













A dissertation submitted to The Johns Hopkins University in conformity with the 

















© 2017 Donald Freed 







Genetic variation arises as the result of both spontaneous and artificial processes. 
While genetic variation and natural selection are the only tools of evolution, genetic variation 
is also known to also cause disease, including inherited disease and cancer. Here we explore 
the consequences of human genetic variation first as a tool for testing identity from a mixture 
of DNA and second as a contributor to autism spectrum disorder. 
Methods 
One of the most comprehensive datasets of human genetic variation across all human 
populations is the 1000 Genomes Project. We use genetic variants from the 1000 Genomes 
Project to identify polymorphic loci in extant human populations using custom computational 
tools. For our studies of mosaic mutation in individuals with autism, we use publicly 
available data and a combination of publically available and custom software.  
Results 
Through our analysis of publically available data, we find genomic loci that may be 
used for identity testing across many human populations. In addition we show that mosaic 
genetic variation detectable in blood contribute significantly to autism spectrum disorder 
while mosaic genetic variants that are unique to affected tissues are not frequently detectable 
from bulk sequence data. 
Conclusions 
Our results have implications for the fields of identity testing and disease genetics. 




individual within a mixture even if that individual’s DNA makes up less than one-millionth 
of the total DNA in the mixture. 
Our identification of a contribution of mosaic mutations to disease has implications 
for our understanding of heritability. In classic measurements of heritability, identical twins 
are used as individuals of constant genetic background and any phenotypic differences 
between identical twins are assumed to come from the “environment”. While genetic 
variation unique to a single individual within a twin pair has been identified, our results are 
the first to indicate that these mutations play a role in the phenotypic differences between 
identical twins. Our results also have implications for the field of genetic counseling. The 
parents of probands with high-confidence mosaic mutations may be less likely to have 
additional children with an autism diagnosis compared to parents with children with ASD 
overall. 
Advisor: Jonathan Pevsner 
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Chapter 1: A Haplotype-Based Method for the Detection of 
Chimerism from Next-Generation Sequencing Data 
1.1 Introduction 
The ability to identify individuals solely on the basis of their DNA sequences has 
revolutionized modern forensics, where blood, semen, or hair found at a crime scene can be 
conclusively linked to a single individual on the basis of polymorphisms at short tandem 
repeats (STR) [1]. While two unrelated individuals may share any given genetic locus, it is 
extremely unlikely that unrelated individuals will share the same alleles across many loci. 
However, these methods are not sensitive for identifying DNA from particular individuals 
that are present at low levels in a mixture. The problem of low sensitivity is especially salient 
when considering individuals who have undergone myeloablative conditioning followed by 
bone marrow engraftment, usually for the treatment of hematological malignancies. After 
treatment, the peripheral blood leukocytes of these individuals will originate from the donor, 
however the observation of peripheral blood leukocytes originating from the patient is 
indicative of cancer recurrence [2].  
Given the low sensitivity of STR-based methods for detection of patient blood 
chimerism, alternative techniques may be fruitful. One especially intriguing method is next-
generation DNA sequencing, which is capable of generating many reads covering a potential 
locus at low cost. The error rate of one of the most popular technologies, Illumina, is around 
1%, indicating that sequencing of a single SNP that is known to be different between the 
patient and donor could potentially improve on the STR-based approach. However, a more 
powerful approach would be to examine loci with haplotypes of SNPs that are different 




sequencing read that originates from the donor actually containing the sequence of the patient 
would be 0.01 to the power of n
 
where n in the number of SNPs present in the patient and 
absent from the donor that are covered by the sequencing read. While this method can be 
used to easily distinguish between different individuals at the HLA loci, other loci may be 
useful for cases where patent and donor have very similar HLA types. To aid in this effort, 
we identified genomic loci that are likely to contain multiple polymorphisms from two 
unrelated individuals using the 1000 Genomes data. 
1.2 Materials and Methods 
Phased variants were downloaded from the 1000 Genomes website (release version 
3_20110521; http://www.1000genomes.org; last accessed July 3, 2014). Loci across the 
genome were then considered for use in the analysis. Loci were considered as candidates if 
they contained at least 9 variants of at least 9% allele frequency in the CEU, JPT/CHB, and 
YRI populations. Given two haplotypes, a comparison between these two haplotypes would 
be considered informative if there were at least two SNP differences between the haplotypes. 
The genetic diversity of candidate loci was then measured as the probability of a comparison 
of haplotypes being informative given that two haplotypes were drawn from the population.  
1.3 Results 
We identified 4,349 loci harboring nine SNPs with allele frequencies of at least 9%. 
Through our analysis we determined that 7 non-HLA loci were likely to be informative at 
least 70% of the time in two individuals drawn at random in the population. Importantly, 
almost all of the identified loci are far enough apart in the genome that they segregate 
independently in the population indicating that testing of multiple loci could increase 





Through the use of publically available data and custom computational methods, we 
identify genomic loci that are likely to be informative when testing for mixtures of DNA 
from distinct individuals. We imagine that these loci will potentially be valuable for testing 
of chimerism in individuals who have undergone myeloablative conditioning followed by 
bone marrow engraftment although more work remains to be done before these loci may be 
used in the clinic. Especially important will be validation of the diversity of these loci across 
a population of patient samples. 
Sensitive methods for detection of chimerism in mixtures have many applications 
outside of bone marrow engraftment monitoring. For instance, this method might be used to 
detect DNA of a suspect at a crime scene, even if the suspect’s DNA is present at a low 
fraction within a mixture. Additionally, a haplotype-based approach may be useful when 
measuring sample contamination, such as contamination of a sample with a technician’s 
DNA that may occur during sample preparation [3].  
In the future, this approach will be aided by the generation of long reads or synthetic 
long reads from third generation sequencing technologies. Already Illumina sequencing 
machines are capable of generating paired 300bp reads, suggesting that the size of the 
genomic loci used in our analysis could be expanded to 500bp or larger. Currently available 
Pacific Biosciences and Oxford Nanopore sequencing machines are capable of generating 10 
kb sequence reads, albeit with much higher rates of errors per base than Illumina sequencers. 
One can imagine that given the known sequence of the donor and patient, these technologies 
may allow for the detection of chimerism with ultra-high accuracy from a relatively small 




Chapter 2: Somatic Mosaicism in the Human Genome 
2.1 Introduction to Somatic Mosaicism 
2.1.1 Early Studies of Mosaicism 
Somatic mosaic mutations are defined as mutations that occur in some cells of the 
soma of a single individual (Figure 2.1) [4,5]. The mixture of mutation-positive cells with 
non-mutated cells results in an individual who is a mosaic, or contains different DNA within 
different cells of his or her body. Mosaic mutations may be present in the germline or soma, 
however, typically only mutations in the soma have phenotypic consequences or are 
detectable by currently available genotyping methods. Mosaic mutations in germ cells are 
usually only discovered when they are inherited by multiple progeny. De novo mutations are 
defined as mutations arising uniquely in a cell that were absent from the cell’s parent cell 
while germline de novo mutations are operationally defined as mutations found in all cells of 
an individual but not detected in that individual’s parents (Figure 2.1 d,e) [6]. De novo 
mutations only present in the offspring may occur very early in development; however, this 
is rare and increasingly sensitive genetic assays are discovering low-level parental mosaicism 





Figure 2.1. Overview of categories of variation.   
Inherited mutations are always transmitted through the germline (a), although a parent may 
also have a somatic mutation (b). In such cases, a child may inherit the variant as a 
heterozygous mutation with a more severe clinical phenotype. A parent may also have 
germline mosaicism which may be inherited by progeny (c). De novo mutations are 
operationally defined as genotypes observed in a child but not in either parent. They may 
originate in a parental germ cell (as may be inferred in a pedigree having multiple affected 
offspring) (d) or postzygotically (e). Somatic mutation may occur relatively early in 









The role of somatic genetic changes in human health has been considered at least 
since 1914 when Theodor Boveri recognized that cancers frequently have abnormal 
karyotypes [9]. Alfred Knudson built upon the work of Boveri and others and in 1971 
described a two-hit model of cancer resulting from both an inherited germline mutation and a 
later somatic mutation  [10]. The model of metastatic cancer occurring as a result of multiple 
mutations in single cells has remained largely unchanged for over forty years [11,12]. 
The scientific community was slower to realize the importance of postzygotic 
mutational events outside of cancer. In the early 1950s, Barbara McClintock demonstrated 
the phenotypic importance of somatic transposition in Zea mays and in 1959 Sir Macfarlane 
Burnet proposed a role for somatic mutation in disease [13,14]. Nonetheless few studies 
indicated that somatic mosaic mutations played a role in human health. This changed in the 
1970s with the discovery that somatic gene rearrangement creates functional diversity of 
immunoglobulin and T-cell receptor genes [15-17]. Today, it is known that somatic 
mutations are ubiquitous [18] and have important roles in cancer [12], aging [19,20], 
neurodegeneration [21], monogenic disease [22-24], reversion of inherited disease [25-28], 
and numerous neurocutaneous disorders [29]. 
2.1.2 Categories of Somatic Variation 
Somatic variation has been observed at all genomic scales from point mutations to 
aneuploidies. At the level of whole chromosomes and large chromosomal segments, complex 
genomic rearrangements occur somatically (as well as in the germline). The loss or gain of 
entire chromosomes is thought to be caused by errors in chromosomal segregation during 
anaphase while non-allelic homologous recombination may cause the loss, gain, or 




events vary considerably based on the size of the event and the genomic region involved. 
In some instances, both copies of a chromosome pair (or of a chromosomal segment) 
are inherited from one parent, a phenomenon termed uniparental disomy (UPD) [32,33]. 
UPD may involve two copies from a parent that are identical (uniparental isodisomy) or 
different (uniparental heterodisomy). Either form may disrupt epigenetically imprinted 
regions (defined as undergoing differential expression depending on the parent of origin), 
while uniparental isodisomy may also expose two copies of a recessive mutation. One 
mechanism for the occurrence of UPD involves trisomic rescue in which an extra (third) 
copy of a chromosome is rejected, producing a diploid cell line in which one parent’s 
monoploid copy is lost [34]. Frequently, the trisomic rescue is restricted to a fraction of cells 
in an individual resulting in mosaic trisomy/UPD [35]. UPD may also result from somatic 
recombination occurring from a reciprocal exchange during mitosis, leading to loss of 
heterozygosity. 
RNA-templated DNA polymerases are another cause of genomic instability. While 
numerous types of repetitive elements are present in human genomes, only non-long terminal 
repeat retrotransposons are currently competent for transposition [36]. Successful 
retrotransposition of these elements is dependent upon functional protein products from long 
interspersed elements (LINEs). In most somatic tissues, LINEs are epigenetically suppressed; 
however, these elements escape epigenetic repression during early embryonic development, 
and their integration into other functional genomic elements occasionally results in disease. 
One example is one case of choroideremia (OMIM #303100) where a patient was found to 
have a full L1 repeat inserted into the coding region of the CHM gene [37]. In somatic tissues 




Low complexity regions, including trinucleotide repeats, are scattered throughout the 
mammalian genome. Trinucleotide repeats can be hypervariable and expansion of some 
trinucleotide repeats is the cause of nearly 30 disorders [39,40]. The molecular mechanisms 
underlying expansion or contraction of these regions are complex and cause these regions to 
have variable length throughout the body of those afflicted with disease [41-47].  
Small genetic aberrations may be caused by a number of mechanisms. Polymerase 
errors may result in nucleotide misincorporation or small insertions or deletions in the 
germline or soma. Over time, DNA will accumulate numerous lesions and DNA 
polymerization across these lesions is especially error-prone. DNA lesions may be detected 
and repaired prior to DNA polymerization, but lesion repair may also create single nucleotide 
variants, or small insertions or deletions [19,48]. Importantly, the process of transcription 
creates single-stranded DNA across genes and this single-stranded DNA is especially prone 
to mutation with a distinct mutational signature [49,50]. 
In linear mammalian genomes, DNA replication starts at multiple origins with DNA 
polymerases ε and δ [51,52]. Polymerase ε moves processively 5’ to 3’ along the genome on 
the leading strand, moving in the same direction as the replication fork. On the lagging strand 
replication by polymerase δ also proceeds 5’ to 3’ but in the opposite direction as the 
replication fork, causing replication of that strand to be iterative. This process works well for 
the majority of the genome, but incomplete replication of the lagging strand leads to loss of 
genetic information at the ends of the chromosome during every replication [53]. This end 
replication problem is solved in the germline as the ends of chromosomes, telomeres, are 
protected by repetitive DNA which is synthesized by a dedicated RNA-templated DNA 




tissues, likely as a method of protection against malignant transformation, and decreased 
telomere length is a form of somatic variation. 
2.1.3 Mosaicism During Development 
A defining characteristic of mosaic mutations is that they occur postzygotically and 
are inherited by all subsequent cells in their lineage (Figure 2.1).  Somatic changes in early 
development are known to induce an extraordinarily high rate of aneuploidy. 15-20% of 
clinically recognized pregnancies result in spontaneous abortion, and half of these are 
attributed to aneuploidy [32]. A review of 36 published studies showed that of 815 human 
preimplantation embryos, only 177 (22%) were diploid while 73% were mosaic for copy 
number alterations [54]. In most cases these were diploid-aneuploid mosaic embryos, having 
one or more diploid cells as well as other cells that were haploid or polyploid for a particular 
chromosome. Mitotic errors could account for the high rate of chromosomal mosaicism.  
Due to the exponential rate of growth during development, somatic mutations must 
occur early in development to have phenotypic effects over large portions of the body. 
Indeed, studies of somatic mutation events from single cells collected across the body 
indicate that mutations that are present in more than approximately 10% of cells in a given 
tissue will be dispersed throughout the body while mutations present at lower frequencies are 
tissue specific [55]. Severe somatic mutations which would be embryonic lethal if inherited 
have an even shorter window during development in which they must occur to be observed in 
adults [23]. Occurring early in development, these mutations are embryonically lethal; 
occurring later in development they may have little or no obvious phenotypic effect. 
Mutations that alter cellular growth do not necessarily have to occur within such a 




activating mutations in oncogenes may have organism-level phenotypic consequences 
regardless of when they occur, as evident from their role in cancer. On the other hand, 
growth retarding mutations, such as inactivating mutations in oncogenes or certain cyclins, 
are unlikely to have phenotypic effect in adults regardless of when they occur in development 
as the total number of cells containing the mutation is likely to be small.  
Somatic mutations are thought to occur in all cells during replication. On average, 50 
mutations occur in microsatellite regions during every mitotic division of a given cell [18]. 
Mutations in microsatellites and other regions of the genome, assessed by either single-cell or 
deep sequencing, can then be used to infer cell lineage trees [56]. To date, the most 
successful lineage tracing experiments have made use of increasingly sophisticated 
microscopic techniques [57]. However, microscopy-based approaches have practical and 
technological barriers such as the requirement that non-transgenic cells must be monitored 
over time. Recent advances in whole genome amplification (WGA) and second-generation 
sequencing (SGS) offer genetic-based approaches that do not have the same limitations. 
Already, these techniques have been used to provide a detailed view of the genetics of cancer 
metastasis [58,59].  
2.1.4. Mosaicism Across the Body 
By definition, somatic mosaic mutations affect only a subset of cells within an 
individual (Figure 2.1). This is most easily visible in monogenic mutations affecting 
pigmentation patterns. While such patterns may be mistaken for stochastic X chromosome 
inactivation or autoimmune response, somatic mutation is generally localized over a small 
portion of the body and in many cases occurs along lines of Blaschko [60]. To date, almost 




abnormalities, usually involving hypertrophy (cellular overgrowth) or abnormal pigmentation 
[29,60]. Some of our inability to identify mutations that do not result in visible phenotypes is 
practical; during dissection it is difficult to distinguish affected from unaffected tissue. 
However, due to the current emphasis on visible phenotypes, few data are available on the 
extent to which non-visible somatic mutations influence important biological processes. 
An important consideration is that somatic mutations occur in varying cell types and 
tissues as well as different developmental stages. This raises the possibility that a specific 
mutation may vary in its clinical importance depending on where the mutation occurs across 
the body. Mutations in GNAQ provide an example. Our lab identified p.Arg183Gln 
mutations in GNAQ, encoding the G protein alpha subunit Gαq, as the cause of both Sturge-
Weber syndrome (OMIM #185300) and port-wine stain birthmarks (OMIM #163000) [61]. 
Port-wine stains are non-syndromic vascular abnormalities while the Sturge-Weber 
syndrome is a severe neurocutaneous disorder, although both conditions likely affect some of 
the same cell types (e.g. endothelial cells). The milder phenotype of the birthmarks could 
result from a later developmental origin of the mutation during fetal development or a 
different cellular lineage harboring the mutation. The identical p.Arg183Gln mutation in 
GNAQ, when occurring in melanocytes during later in life contributes to uveal melanoma, 
highlighting the importance of both the location and timing of the mutation. p.Arg183Gln 
mutations in different cell types and developmental stages could have different phenotypic 
consequences, if any [62].  
Other mosaic mutations also differ in their clinical importance based on cell or tissue-
specific involvement. McCune-Albright syndrome (OMIM #174800) is characterized by 




dysplasia. These symptoms can vary considerably based, in part, on the extent of the 
mutation [63]. Like Sturge-Weber syndrome, this disorder is caused by somatic activating 
mutations in a gene encoding a G protein alpha subunit (GNAS encoding Gαs). Expression of 
this gene highlights another dimension of mosaicism. GNAS is expressed biallelically 
through most of the body, but the maternal allele is imprinted in particular tissues such as the 
pituitary. The disorders progressive osseous heteroplasia (OMIM #166350) and 
pseudopseudohypoparathyroidism (OMIM #612463) result from loss of function mutations 
in the paternal allele of GNAS [64]. 
Somatic mutations in three AKT genes also have cell-specific effects [65-67]. Somatic 
AKT1 mutations are associated with somatic breast cancer, colorectal cancer, and ovarian 
cancer as well as the Proteus syndrome. The AKT2 gene is expressed selectively in insulin-
responsive tissues and mutations are associated with diabetes. Somatic mutations in AKT3 
cause Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2 (OMIM 
*611223). Given the localized nature of somatic mutations in AKT discovered to date, it is 
likely that mutations in these genes occurring outside of vulnerable cell types have few 
effects. These examples highlight the complex interaction of localized somatic mutation with 





Figure 2.2. Tissue-specific effects of mutations in GNAQ, GNAS and AKT1, AKT2, 
and AKT3.  
Constitutively activating mutations in GNAQ may lead to either Sturge-Weber syndrome, 
nonsyndromic port-wine stain, or uveal melanoma (A). Somatic activating mutations in 
GNAS lead to McCune-Albright syndrome which may involve variable hyperthyroidism, 
café au lait macules and sexual precocity (B). Activating mutations in all three of the 
AKT genes cause cellular overgrowth phenotypes with mutations in AKT2 also 






Numerous studies have aimed to assess the prevalence of mosaic alterations in tissues 
of apparently normal individuals. Reanalysis of data from multiple large genome-wide 
association studies have determined that the number of detectable mosaic events rises sharply 
after age 50. Furthermore, individuals with increased numbers of mosaic events have higher 
risk for developing cancer [68,69]. While this measured increase of mosaicism may be due to 
increased rates mutation rates in elderly individuals, it is much more likely that these events 
are the result of clonal expansion and positive selection within the stem cell niche or decline 
in the total number of hematopoietic stem cell progenitors later in life. Notably, increased 
rates of mosaicism in apparently normal tissues have been linked to poorer prognosis in 
individuals with ovarian cancer [70]. 
Studies of twins have demonstrated that post-zygotic mutations may be 
phenotypically important. Notable examples are monozygotic twins who are discordant for 
phenotypic sex due to mosaic loss of chromosome Y [71,72]. Numerous examples of 
monozygotic twins exist where either the presence [73,74] or severity [75] of disease is 
discordant between twin pairs due to variable proportions of mosaic cells. 
Studies of multiple tissues of apparently normal individuals have also found evidence 
for mosaic events. Analysis of CNVs using hybridization of DNA from multiple tissues of 
three apparently normal individuals to bacterial artificial chromosome arrays found evidence 
for six somatic CNVs [76]. Higher resolution examination of a total 33 tissues from six 
individuals using array comparative genomic hybridization found evidence for 73 high-
confidence mosaic CNVs, although a majority of high-confidence events (54/73) were found 
in one of two particular tissues [77]. It has been noted that induced pluripotent stem cells 




the process of immortalization. Abyzov et al. performed a detailed study of this phenomenon 
and concluded that almost half of CNVs present in iPSC lines can be found in the parental 
fibroblasts. Furthermore, they conclude that approximately 30% of all fibroblasts in their 
sample contain some mosaic CNVs [78]. 
While experimentation with bulk tissues has shown that somatic mosaicism occurs 
frequently in normal populations, the combination of DNA from many cells limits the ability 
of an assay to detect mosaic events unique to single or few cells. As a result, sequencing of 
single-cells has been recently used to assay mosaicism in normal tissues. These methods have 
been used to sensitively reexamine conclusions regarding the extent of mosaicism in the 
brain. Previous reports had indicated that up to 33% of neuroblasts were aneuploid while up 
80 retrotransposon insertions occur per neuron [79-82]. Single-cell experiments of the same 
phenomena have shown that large copy-number variants occur in over 14% of neurons but 
whole chromosome aneuplodies and retrotransposition events are relatively rare [83-85]. 
Single-cell studies have also been used to investigate the extent to which mosaicism 
occurs in early development. It has been known since 1983 that chorionic villus sampling 
may indicate the presence of a trisomy, while the fetus is diploid without the presence of 
mosaicism, a condition termed confined placental mosaicism [86-88]. Single-cell studies of 
young embryos cultured in vitro also demonstrate that chromosomal aneuploidies are 
common and were found in 83% of tested embryos [89]. While it is likely that many 
aneuploid embryos are unlikley to result in viable pregnancies, recent advances in prenatal 
testing allow for the sensitive and specific detection of numerous trisomies by sequencing of 
circulating fetal DNA from maternal plasma [90]. 




2.2.1. Technical Considerations 
Almost every type of genetic variation has been implicated as a source of somatic 
variation including expansion of trinucleotide repeats, point mutation, copy-number loss/gain, 
uniparental disomy, mitotic recombination, aneuploidy, translocation, and retrotransposition 
[41-44,47,73,81,84,91-99]. The techniques summarized below vary widely in their ability to 
detect specific types of somatic variation and more specialized techniques exist for the 
sensitive detection of some types of variation. 
A primary consideration during the analysis of mosaic samples is the purity of the 
dissection from tissue samples. The presence of normal cells in affected tissue significantly 
decreases the ability to detect mosaic alterations. This problem can be compounded by the 
fact that cellular migration during development is prevalent in some tissues. Thus, in a tissue 
affected by a somatic mutation, two neighboring cells may both be affected if they share a 
common lineage from the mutated cell. Alternatively, cellular migration could cause 
neighboring cells to originate from distinct precursors with only one cell affected. Cellular 
migration can place an important biological constraint on the visible frequency of driver 
somatic mutations in affected tissues (e.g. in the brain) [6,100,101]. 
While contamination of normal cells is known to decrease the observed frequency of 
mosaic mutations, other mechanisms may decrease the detectable fraction of mosaic cells 
within a sample. Two possibilities are cell-type specific lethality and mosaic absence of 
essential juxtacrine or paracrine signaling factors. Cellular signaling pathways are known to 
have cell-type specific effects raising the possibility that a mosaic mutation may be lethal in 
only one type of cell within a tissue. Furthermore, some paracrine or juxtacrine signaling 




affected tissue that is dependent upon surrounding normal tissue for survival, reducing the 






Figure 2.3. Cell death may reduce the total number of cells harboring somatic 
mutation.  
Mosaic mutations may cause cell-type-specific lethality (A). Mosaic loss of an essential 
juxtacrine signaling factor may cause localized cell death of cells are not adjacent to 






In Sturge-Weber affected tissues, detected GNAQ mutant allele frequencies were 
between 1 and 18% [61]. Other studies using similar techniques have detected mutant allele 
frequencies of 1-47%,[66] 3-30% [105], and 3-35% [65] for causative mutations in 
individuals with Proteus syndrome (OMIM #176920), CLOVES (OMIM #612918), and 
hemimegalencephaly (e.g. OMIM #611223), respectively. Such relatively low allele 
frequencies are likely explained by the presence of low proportions of affected cells in a 
given tissue.  
In second-generation sequencing experiments, sequencing and mapping errors are a 
major concern, as some portions of the genome are known to be prone to false-positive 
variant calls [106]. Recent improvements in sequencing chemistry have lowered the 
frequency of sequencing errors. However, biased errors in sequencing are still problematic 
for the detection of somatic variation, especially when the mutant allele frequency may be 
close to the technology’s inherent error rate. Generally, ultra-high depth sequencing (> 500 
reads) of normal and affected tissues will permit detection of these errors. However, 
exploratory studies generally do not reach this level of depth. It is likely that without 
validation, these errors are a source of false positives in somatic variation databases. 
Comparing suspected somatic mutations across multiple tissue types from multiple 
individuals may be a possible solution to this problem [107]. 
2.2.2. Cytogenetics  
Microscopy-based methods allow for the detection of large mosaic events in single 
cells. Early cytogenetic methods for identifying extra or fewer chromosomes involved 
counting condensed metaphase chromosomes under a microscope [108]. Later methods using 




identification of intra- and interchromosomal translocations, duplications, deletions, and 
large structural rearrangements. However, this method can only resolve aberrations larger 
than 3-10 Mb [109]. Other methods, such as fluorescent in situ hybridization (FISH), label a 
specific region of the genome by hybridization of a fluorescent probe allowing for the 
detection of deletions and some duplications [110]. Variations in this methodology exist 
using multiple probes of different color to detect several unique fragments at a time (i.e. 
multicolor FISH). These methods are able to achieve resolutions below 100 kilobases or, in 
some cases, as few as several kilobases [111]. Potential probe binding to off-target regions is 
a major consideration in most FISH experiments and adequate controls are required to 
confirm locus specificity [111]. Variants on classical FISH methods continue to be developed 
which promise to increase the ability of fluorescent probes to detect small chromosomal 
abnormalities across increasingly large portions of the genome [111,112]. In combination 
with high-throughput techniques, these approaches may be used to screen large numbers of 
cells from a single individual allowing for the detection of low levels of mosaicism.  
2.2.3. Genome-Wide Arrays 
Comparative genomic hybridization (CGH) is a technique in which 
fluorophore-labeled DNA from a control and test individual are hybridized to a metaphase 
reference chromosome [113]. The ratio of fluorescence emission is then measured to allow 
for the detection of duplication or deletions. A ratio of 1:1 indicates that both samples of 
DNA carry the same copy number while deviations from this ratio indicate a copy number 
variant [114].  
Two principal array-based techniques that have emerged as alternatives to CGH are 




[115-117]. Similar to CGH, both aCGH and SNP microarrays have the ability to detect 
changes in copy number over large regions of the genome. SNP microarrays further have the 
ability to genotype individuals at the probed sites, which may be useful in the detection of 
low-level somatic events [118]. Array-based approaches offer increased sensitivity over the 
entire genome for small CNVs relative to genome-wide microscopy-based approaches. 
aCGH and SNP microarray analysis can resolve regions less than 100 kb in size. However, 
the sensitivity of array-based approaches for somatic CNVs is dependent on having at least 
5%–10% of the cells assayed containing the genetic variant. For larger CNVs affecting a 
smaller fraction of cells, microscopy-based approaches are more sensitive. 
In both aCGH and SNP microarrays, deviations in relative probe intensities indicate 
deletion or insertion events. Normalized probe intensities are commonly reported as log-R 
ratios with higher intensities indicating insertions while lower intensities indicate deletions. 
For SNP microarrays, the relative intensities of the two probes (one specific to each allele) at 
a locus is informative and normalization of these intensities is measured as a B-allele 
frequency. For normal diploid tissues, B-allele frequencies approximate 0.0, 0.5, and 1.0 for 
AA, AB, and BB genotypes, respectively, while Log-R ratios approximate 0 across diploid 
regions. 
The hybridization of genomic DNA to microarrays is inherently noisy and can be 
subject to large batch effects [119]. Furthermore, individual probes or even whole arrays may 
have errors caused by faulty manufacture. Together these artifacts make the detection of 
statistically significant mosaic CNVs difficult, but many software packages exist to aid in the 
detection of these events. Numerous tools use hidden Markov Models to integrate B-allele 




PennCNV-2, GPHMM and MixHMM [120-122]. gBPCR uses an approach similar to the 
Bayesian piecewise constant regression for the detection of mosaic abnormalities but has a 
long runtime per sample [123]. Our lab developed triPOD which uses multiple algorithms for 
the detection of mosaic events and is unique in that it utilizes parental genotypes allowing for 
more sensitive detection of haplotype-specific mosaic abnormalities [118]. 
2.2.4. Second-Generation Sequencing   
Second-generation sequencing techniques have revolutionized human genetics in the 
last decade. Sequencing is performed either on single cells, a discrete number of cells, or 
bulk tissue. In the typical sequencing experiment, DNA is extracted from the input material 
and is fragmented, end-repaired, size-selected, and sequenced with the end result being 
strings of inferred nucleotides and their respective quality scores [124]. This information is 
used to align the sequencing reads to a reference genome. Differences between the aligned 
reads and the reference can be used to infer genetic variants including single-nucleotide 
variants or polymorphisms (SNVs or SNPs), insertions, deletions, translocations, and 
retrotransposition events. Furthermore, the total number of reads aligned to certain regions of 
the genome can be used to infer copy-number changes [125,126]. Numerous variations on 
this basic approach exist and here we will discuss the methods most applicable for the 
detection of mosaic events. 
Somatic genetic variants have been discovered via whole-exome or whole-genome 
sequencing of bulk tissue from paired affected and unaffected portions of the body 
[61,65,66,105]. Whole-exome sequencing relies upon an oligonucleotide array-based capture 
of DNA fragments corresponding to exonic regions to reduce the sequence from noncoding 




considered to have similar sensitivity for most pathogenic SNVs and small insertions or 
deletions. Whole-exome sequencing is considered less sensitive for the identification of 
medium to large insertions or deletions or the detection of copy-number changes by analysis 
of read depth due to introduced biases. However, exome sequencing experiments are 
typically carried out at higher depth due to the lower cost of the method.  
Numerous software packages allow for the identification of somatic variants from 
second-generation sequence data. Somatic variant callers typically evaluate next-generation 
sequence data from paired tumor/normal (or other affected/unaffected) samples. Examples 
include VarScan2 [126], SomaticSniper [130], JointSNVMix [131], Strelka [132], and 
MuTect [133]. After removal of low-quality reads, sequences are aligned to a reference 
genome to generate aligned binary sequence alignment/map (BAM) files [134]. At least three 
approaches have been employed for the detection of SNVs and small insertions or deletions. 
(1) Allele frequencies can be compared. For examples, VarScan2 performs pairwise 
comparisons of base calls and normalized sequence depth at each position, accounting for 
factors such base quality scores, coverage and variant allele frequencies. (2) Bayesian 
comparison of joint diploid genotype likelihood can be estimated for both samples. The 
SomaticSniper algorithm calculates the statistical significance of all somatic variants at 
positions above a minimum threshold of coverage using this method. (3) Other Bayesian 
approaches have been applied. For example, Strelka models the normal sample as germline 
variation plus noise, while the affected sample includes noise along with germline and 
somatic variation. Other types of somatic variation may be detected from bulk sequencing. 
Tools such as VarScan2, ADTeX, Control-FREEC, SomatiCA, and LUMPY may be used for 




Besides variant identification, quantification of the fraction of cells affected by 
particular somatic changes provides a better understanding of the extent of the mosaic 
mutation and the period during development at which it occurred. Several tools have been 
developed to deconvolute somatic mutations into distinct populations as reviewed by Yadav 
and De and Ding et al. [139,140]. 
An alternative approach to sequencing bulk tissue is sequencing single cells or 
small numbers of cells. Amplification can greatly increase the total amount of available 
DNA for sequencing at the expense of introduced biases such as allele dropout and 
chimeric amplification of genomic fragments [84,141-143]. Despite these introduced 
biases, amplification and subsequent second-generation sequencing or array-based 
analysis of single cells has been used to reliably find somatic copy number variation and 
retrotransposition events within the human brain as well as to map cell lineage within a 
bulk tumor dissection [58,59,84,144]. Numerous groups have also used single-cell 
techniques to discover SNVs or indels in single cells, however, allelic dropout and 
chimeric amplification are more problematic for these analyses as biases can be reduced 
for analysis of CNVs by increasing bin sizes but are more difficult to account for in 
analysis of SNVs [145-147]. 
2.3 Somatic Mosaicism in Disease 
2.3.1. Cancer and Aging 
The relationship between somatic mutation and cancer has been extensively reviewed 
elsewhere [12,20,97,148-150] and comprehensive lists of known oncogenes or tumor 
suppressors or genes significantly and recurrently mutated in cancer have been previously 




evading growth suppressors, resisting cell death, enabling replicative immortality, induction 
of angiogenesis, and inactivating invasion and metastasis [151]. Driver gene mutations are 
defined as conferring a selective growth advantage in tumor cells [12]. This may be achieved 
by elevating the activity of growth factors and/or their receptors, but more commonly driver 
mutations constitutively activate intracellular signal transduction cascades. Three of these are 
depicted in Figure 2.4 (in simplified form): Ras/Raf/MEK/ERK, Ras/PI3K/PTEN/Akt/mTOR 
[152], and GNAQ. These pathways contain both oncogenes (RAS, RAF, MEK, PIK3CA, AKT, 
GNAQ) and tumor suppressor genes (NF1, PTEN, TSC1, TSC2). For example the RAS 
family of oncogenes were the first oncogenes to be identified in cancer. Comprised of HRAS, 
KRAS and NRAS, activating mutations in these genes occur in approximately 20% of all 
cancers [153]. Germline variants are also well known to contribute to cancer morbidity [154-
156]. Frequently, these variants affect proteins involved in DNA repair, highlighting the role 





Figure 2.4. Signaling pathways in mosaic disease and cancer. 
Three intracellular signaling pathways are shown schematically. At left, receptor 
tyrosine kinase activity leads to activation of PIK3CA, AKT, and mechanistic target of 
rapamycin (mTOR) [159,160]. mTOR participates in complexes (TORC1, activated by 
RHEB; TORC2, inhibited by RHEB) that regulate cell growth, proliferation, survival, 
and cell cycle progression. This pathway includes genes that are frequently mutated in 
tumors such as PIK3CA and PTEN (not shown). At center, secreted growth factors bind 
to receptor tyrosine kinase receptors on the cell surface leading to activation of the low 
molecular weight G protein Ras and subsequent activation of Raf, MEK 1/2, and ERK 
1/2 (official gene symbols MAPK3, MAPK1). At right, a G-protein coupled receptor 
(GPCR) pathway is shown [157,158]. Ligands such as vasopressin, endothelin, 
glutamate, or norephinephrine bind to a GPCR. When bound by ligand, the receptor 
activates a G protein alpha subunit such as Gαq that binds and hydrolyzes GTP. This 
leads to activation of phospholipase Cβ producing inositol 1,4,5-triphosphate (IP3) and 
membrane-associated diacylglycerol (DAG). DAG, through activation of protein kinase 
C, may activate the Raf/MEK/ERK pathway. IP3 may bind to an IP3 receptor activating 
calcium signaling pathways (not shown). Other G protein α subunits (such as Gαs 
encoded by GNAS) activate membrane-bound adenylate cyclase, producing cyclic AMP 









In common solid tumors, ~95% of protein altering mutations consist of single base 
substitutions, >90% of which are missense mutations, <8% are nonsense mutations, and <2% 
affect splice sites or untranslated regions [12]. Relatively large numbers of somatic mutations 
occur in tumors that are associated with mutagens such as ultraviolet light and cigarette 
smoke. For example, in non-small cell lung carcinomas the average mutation frequency is 
greater than ten-fold higher in smokers compared to those who never smoke [161]. 
Large-scale projects and databases have been developed to provide comprehensive 
catalogues of somatic mutations found in cancer [162,163]. COSMIC (Catalogue Of Somatic 
Mutations In Cancer) includes information on more than 1.6 million mutations from nearly 1 
million cancer samples and includes various types of mutations (fusions, genomic 
rearrangements, whole genomes, and copy number variants) [163]. 
The combination of well-characterized somatic mutation databases and low-cost 
sequencing technologies may lead to improved patient outcomes in the near future. Biopsied 
tumors may be screened rapidly for putative driver mutations based on cancer type, 
informing treatment. Furthermore, once a cancer is in remission, tumor-specific DNA may be 
assayed at low cost with ultra-sensitive second-generation sequencing-based techniques 
[164]. These advances will likely improve prognosis for millions of cancer patients within 
the next decade. 
The primary risk factor for cancer is age, and cancers offer insight into age or 
mutagen-associated mutational processes [165]. Somatic mutations have long been suspected 
to be an important part of the molecular mechanism of aging, and accumulation of DNA 
lesions and mutations occurs in both the germline and soma over time [68,69,166,167]. By 




hampered cellular function. As visible in cancers, the characteristics of acquired mutations 
differ by tissue type and are dependent upon environmental exposure [12]. Furthermore, 
frequently dividing stem cells and frequently transcribed genomic regions have different 
patterns of mutation that are cell-type specific. 
In both mouse and human, increased rates of somatic mutation and numbers of DNA 
lesions due to either error-prone DNA polymerases or faulty DNA repair mechanisms cause 
cancer predisposition, early aging, and neurodegenerative phenotypes [20]. Increased rates of 
somatic mutation in the nuclear genome cause cancer predisposition, likely due to increased 
rates of mutation in somatic stem cell populations. This has been demonstrated in transgenic 
mice whose processive DNA polymerases lack proofreading. Notably, mice with mutated 
polymerases δ and ε develop distinct cancers but do not demonstrate premature aging 
phenotypes [168-170]. While these mice may not live long enough to demonstrate early 
aging phenotypes, their predisposition towards the development of cancer demonstrates a 
strong link between cancer and somatic mutation. 
Mutations in genes affecting other pathways demonstrate a strong relationship 
between somatic mutations and aging. Mice with error-prone mitochondrial polymerases 
demonstrate a premature aging phenotype without cancer predisposition, although 
subsequent data by some of the same authors demonstrate that mitochondrial point mutations 
are unlikely the primary cause of aging in normal mice [171,172]. Individuals with defects in 
DNA repair also demonstrate symptoms of progeria. Cockayne syndrome (OMIM #216400) 
is caused by defects in transcription-coupled exonucleotide repair leading to an early aging 
phenotype combined with intellectual disability and neurodegeneration without noted 




helicases cause Werner syndrome (OMIM #277700) and Rothmund-Thomson syndrome 
(OMIM #268400) [174]. The most prominent phenotype of individuals affected by these 
diseases is premature aging, although these individuals are also predisposed to developing 
cancer [174]. Bloom Syndrome (OMIM #210900) is notable in that it is also caused by 
mutations in a RecQ helicase-like protein and also increases cancer incidence, but does not 
appear to result in progeria. Mutations in numerous other genes are known to cause cancer 
predisposition. One such example is BUB1B. Loss of BUB1B protein function leads to 
premature chromatid separation and mosaic variegated aneuploidy syndrome 1 (OMIM 
#257300) typically resulting in cancer predisposition and intellectual disability [175]. 
Cancer is associated with many genomic changes. Large chromosomal changes occur 
in a variety of noncancerous conditions. An example is Pallister-Killian syndrome (OMIM 
#601803) is a dysmorphic condition caused by mosaicism for tetrasomy 12p. Affected 
individuals display tissue mosaicism, typically with apparently normal karyotypes from 
lymphocytes but 47 chromosomes in skin fibroblasts and chorionic villus and amniotic fluid 
cells. The extra chromosome is an isochromosome for a portion of chromosome 12p. In 
several cases hexasomy of chromosome 12p has been observed.  
2.3.2. Neurodegenerative Disease  
Somatic mutation is suspected to have a role in neurodegenerative disease [20,21]. As 
in cancer, mutations in genes directly involved in DNA repair are implicated in 
neurodegenerative diseases such as ataxia-telangiectasia (OMIM #208900) and ataxia-ocular 
apraxia 1 (OMIM #208920) [19,174,176-179]. These neurodegenerative phenotypes are 
likely caused by an increase of somatic mutation in the nervous system leading to cellular 




related neurodegenerative disorders. 
There is evidence that mosaic mutations or accumulated damage to other 
macromolecules play a role in Alzheimer’s disease (OMIM #104300) and Creutzfeldt-Jakob 
disease (CJD) (OMIM #123400). Alzheimer’s disease is characterized by the accumulation 
of β-amyloid (Aβ) plaques while CJD is caused by misfolded protein PRNP [180,181]. 
Significant incidence of both diseases is attributed to familial risk and causal mosaic 
mutations have been found in sporadic cases [182,183]. Aβ plaques have long been 
implicated in the formation of prions and introduction of Aβ plaques into the brains of mice 
overexpressing Aβ leads to disease progression [184-186]. Consistent with the link to prions, 
the pathology of inoculated mice displays phenotypes dependent upon the infecting host 
[186]. This has been corroborated by more recent experiments, which demonstrate that Aβ 
aggregates from distinct sources have unique biophysical characteristics depending on the 
seeding protein [187-189]. While it is possible that sporadic misfolded or damaged proteins 
act as seeds in Alzheimer’s, this is unlikely given the steep increase in disease incidence later 
in life and the constant turnover of cellular proteins [190]. This steep rise in incidence 
mirrors the rise in incidence of CJD in individuals who have predisposing mutations [191]. It 
is possible that in both diseases misfolded proteins arising as a result of age-related somatic 
mutation or damage to other macromolecules in single cells act as seeds for the initial protein 
aggregates. 
2.3.3. Monogenic Disease 
A list of diseases suspected to be caused by obligatory somatic mutations has been 
previously described [22] and subsequently updated [23,24]. We note that somatic mutation 




We have described a series of oncogenes and tumor suppressor genes that undergo 
somatic mutation in cancer. These same genes can also acquire somatic mutations that result 
in neurocutaneous disorders or overgrowth syndromes, depending the particular cell type and 
developmental stage at which the mutation occurs. Mutations in GNAQ cause Sturge-Weber 
syndrome and port-wine stain birthmarks as well as uveal melanoma, as discussed above. 
Similarly, somatic mutations in GNAS can cause McCune-Albright syndrome or benign 
tumors such as adenomas. We next highlight several specific examples of such disorders 
affecting genes encoding intracellular signaling pathways (Figure 2.4). 
Phosphatidylinositol 3-kinases (PIK3s) are lipid kinases that phosphorylate 
phosphatidylinositol and other phosphoinositides, catalyzing intracellular signaling pathways 
involving a PI3K/AKT/mTOR network (Figure 2.4). Somatic, mosaic, gain-of-function 
mutations in PIK3CA (OMIM *171834) are associated with several syndromes involving 
overgrowth of the brain or lipomatous body overgrowth [192]. These include CLOVE (an 
acronym for congenital lipomatous overgrowth, vascular anomalies, and epidermal nevi) 
syndrome, megalencephaly-capillary malformation syndrome, fibroadipose hyperplasia, and 
hemimegalencephaly. These conditions are often characterized by early segmental 
overgrowth, abnormal vasculogenesis, digital anomalies, cortical brain malformations, and 
connective tissue dysplasia. Somatic gain-of-function mutations in PIK3CA are also found in 
a broad range of cancers (ovarian, breast, lung, stomach, colorectal, and brain). While over 
100 activating mutations in PIK3CA are known, mutations in two domains of the protein 
account for 80% of cancer-associated somatic mutations, and these same sites can be mutated 




Clinical presentation of Proteus syndrome (OMIM #176920) includes distorting, 
progressive overgrowth of various tissues including skin, skeleton, adipose, and central 
nervous system. In most patients it is caused by somatic mosaic mutation of AKT1 involving 
c.49G>A (p.Glu17Lys) [66]. This identical mutation was previously known to be associated 
with breast, colorectal and ovarian cancers [194]. The holomlogues of AKT1; AKT2 and 
AKT3 are also known to cause somatic disorder. p.Glu17Lys mutations in AKT3 cause 
hemimegalencephaly and other brain malformations, while the identical mutation in AKT2 is 
causative for hypoglycemia [65,67,195,196].  
Germline inactivating mutations in the TSC1 gene encoding hamartin cause tuberous 
sclerosis 1 (OMIM #191100), while mutations in TSC2 encoding tuberin cause tuberous 
sclerosis 2 (OMIM #613254). Hamartin and tuberin to act as tumor suppressors by activating 
the GTPase function of RHEB [197]. Inactivating mutations in a single allele are sufficient to 
cause tuberous sclerosis as rare somatic inactivating mutations, lack of expression of the 
second allele or mosaic UDP events give rise to the multiple benign tumors, tubers and 
macules characteristic of the disease [198,199]. 
Neurofibromatosis 1 (OMIM #162200) (NF1) is characterized by the occurrence of at 
least two (of a list of seven) features such as café au lait spots, cutaneous neurofibromas, 
Lisch nodules (hamartomas) of the iris, and inguinal freckles [200]. Clinical diagnosis 
requires a first-degree relative with the condition. It is inherited in an autosomal dominant 
manner (and is among the most common such disorders with a prevalence of 1:3000). Most 
cases of NF1 are caused by heterozygous loss-of-function mutations of the tumor suppressor 
gene encoding neurofibromin 1. But only 50% of NF1 individuals have an affected parent, 




ras signal transduction pathway, with loss of function mutations in neurofibromin 1 leading 
to RAS activation. 
It is possible that mosaic variation occurring during development may result in 
disease across numerous tissues. One such example is somatic mutation of IDH1 and IDH2 
that has been shown to cause Ollier disease and Maffucci syndrome. These syndromes are 
characterized by multiple enchondromas (benign bone tumors originating from cartilage). 
The causative variants for disease are typically not detectable outside of the tumors 
indicating that relatively few cells harbor the mutation [201]. 
The application of sensitive approaches for the detection of mosaicism to a smaller 
subset of genes based on a patient’s phenotype may increase the likelihood of finding 
causative variants. Jamuar et al. applied this approach examining two sets of previously 
implicated genes in 158 individuals with cerebral cortical defects. Causal mutations were 
found in 27 individuals, eight of who harbored the causative variant in a mosaic fashion. 
Notably, causal mutations were only validated at extremely high read depth (>500×) 
highlighting both the importance of sequence coverage for the detection of mosaic variation 
and the utility of targeted approaches [202]. 
 Somatic mutations are also known to cause reversion to normal mutations in individuals 
with monogenic disease [25,26,28,203,204]. Revertant mosaicism occurs when cells 
harboring a disease-causing mutation revert in vivo to a wild-type allele. The disease-causing 
mutation could be inherited from the germline or somatic. This has been observed for 
heritable skin diseases such as ichthyosis with confetti (OMIM #609165) and epidermolysis 
bullosa (OMIM #226650) [203,205] as well as rare blood disorders such as Fanconi anemia 




deaminase deficiency (OMIM #102700) [206,207]. These somatic reversions to normal 
events may significantly ameliorate disease symptoms if the reversion occurs early enough in 
development. 
For many other overgrowth syndromes somatic mutations have yet to be identified. 
Examples include Klippel-Trenaunay-Weber syndrome (OMIM %149,000), which involves 
cutaneous hemangiomata and clinically resembles Sturge-Weber syndrome; and Cobb 
syndrome (cutaneomeningospinal angiomatosis), which involves vascular cutaneous, 
muscular, osseous, or other lesions of spinal segments. 
2.3.4. Complex Disease 
Multiple recent papers have proposed that somatic mutation may play a role in the 
etiology of complex disease [6,208,209]. Studies of simplex autism probands have 
determined that de novo mutations account for 10%–20% of disease incidence and that at 
least 30% of de novo mutations can be causally implicated in simplex cases [210-213]. With 
de novo mutations playing such a large role, it is likely that post-zygotic somatic variation 
also contributes to disease in some individuals. To date, most genetic analysis has found few 
genetic variants to explain complex disease incidence, suggesting the occurrence of “missing 
heritability” [214]. A possible model is that somatic variation occurs in conjunction with 
common and rare inherited variation to cause disease. While this model is not directly 
supported by current evidence, recent experiments indicate that it warrants investigation. One 
surprising result from in situ hybridization experiments on postmortem brain tissue is the 
increased presence of patches of cortical disorganization in individuals with autism relative 
to controls [215]. The authors note that they examined only a small subsection of the brain 




Furthermore, an interesting conclusion of recent large-scale examination of exonic de novo 
mutations in simplex autism is that most de novo variation implicated as causal occurs 
opposite wild type alleles [212]. Given that large CNVs are common in neurons of the cortex 
[83,85], we propose a model of brain-specific somatic mutation occurring opposite inherited 
de novo or rare mutation resulting in sporadic brain-specific loss of gene function and 
patches of cortical disorganization. 
2.4. Conclusions 
While the role of somatic mosaicism in disease currently under active 
investigation, it is clear that functional somatic mosaicism has a significant role in 
human disease. In the last decade, major advances in both cytogenetic and second-
generation sequencing techniques have enabled researchers to discover causative 
somatic mutations for an increasing number of diseases, and driver mutations in an 
increasing number of cancers. Furthermore, this increased understanding of the genetic 






Chapter 3: The Contribution of Mosaic Variants to Autism Spectrum 
Disorder 
3.1 Introduction 
DNA is constantly exposed to natural and artificial mutagenic processes and therefore 
continually develops lesions and undergoes subsequent error-prone repair. In multi-cellular 
organisms, these mutations may arise at any time during development resulting in diverse 
organismal and cellular phenotypes, including disease. The severity of these phenotypes is 
dependent upon not only the particular genetic change but also the affected cell type and time 
in development at which the mutation occurs. Obligatory somatic disorders, in which 
prenatally lethal germline mutations occur post-zygotically, are one extreme [29].  
In contrast to obligatory somatic mutation, de novo mutation is thought to primarily 
occur in the parental germline, typically resulting in genetic variation that is heterozygous in 
every cell of an organism. Such mutation is de novo in the sense that it is below the limit of 
detection in a parental sample (usually DNA derived from blood). An early report using 
comparative genomic hybridization indicated that large de novo copy-number variants are 
enriched in ASD probands [216]. From these results it was hypothesized, and subsequent 
microarray and whole-exome sequencing experiments have shown, that a substantial fraction 
of genetic liability arises de novo in every generation [212,217-228].    
The exact developmental time at which de novo mutations occur however, is under 
active investigation. Some de novo variants discovered though whole-exome sequencing 
have properties consistent with mosaicism [222,225,229,230]. Recent experiments using 
high-depth targeted sequencing have indicated that eight of 27 likely causal variants in 




alternate-allele reads fractions (AARF) [202]. Mosaic mutations have been found to occur in 
single individuals of monozygotic twin pairs [231,232]. Furthermore, 6.5% of identified de 
novo mutations in individuals with severe intellectual disability occur as mosaics [233]. Here 
we show that de novo variation in a large whole-exome sequencing dataset is frequently 
mosaic and that such mosaic variation is likely to contribute to disease diagnoses in some 
affected individuals.  
3.2 Materials and Methods 
3.2.1 Paired sample whole-exome sequencing  
Paired samples were obtained from the University of Maryland Brain and Tissue 
Bank as detailed in Table 3.1. Individuals were diagnosed with ASD (n=12) or were 
controls; criteria for diagnosing ASD included the Autism Diagnostic Interview-Revised 
(ADI-R), Childhood Autism Rating Scale (CARS), and Autism Diagnostic Observation 
Schedule (ADOS) as detailed Table 3.1. DNA was extracted from tissue dissections 
according to protocols in the QIAGEN Genomic DNA Handbook. Exonic regions were 
selectively captured using Agilent SureSelectXT Human All Exon V5. Sequencing was 
performed at the Center for Inherited Disease Research at Johns Hopkins generating 100 bp 
sequence reads on an Illumina HiSeq. CIDRSeqSuite version 3.0.1 was used for processing 
of the raw data files. BCL files were converted to qseq format using Illumina’s BCL 
converter. qseq files were then demultiplexed and converted to FASTQ files using a custom 
demultiplexer. Paired-end alignment was performed using BWA aln to the 1000 genomes 
hg19/GRCh37 reference genome [234]. SAM files were sorted, converted to BAM, and 
duplicates were marked with Picard. GATK was used for local realignment and base quality 







Table 3.1 Tissue samples obtained from the University of Maryland Brain and Tissues Bank. 
PMI, postmortem interval. 
Brain 
Bank ID 







  Years Days   Hours Years Days      
1349 ASD 5 220 M Caucasian 39 13 268      
4722 Control 14 198 M Caucasian 16 9 234 N/A N/A N/A N/A N/A 
4671 ASD 4 165 F African 
American 
13 9 226 26 n/a 13 3 5 
4849 ASD 7 171 M African 
American 
20 8 243 22 18 n/a 8 3 
4907 Control 4 274 F African 
American 
15 7 69 N/A N/A N/A N/A N/A 
4999 ASD 20 274 M Caucasian 14 6 22 n/a n/a n/a n/a n/a 
5144 ASD 7 55 M Caucasian 3 6 316 28 20 12 3 3 
5278 ASD 15 324 F Caucasian 13 5 310 22 21 11 5 5 
5391 Control 8 286 M Caucasian 12 4 258 N/A N/A N/A N/A N/A 
5408 Control 6 309 M African 
American 
16 4 145 N/A N/A N/A N/A N/A 
5419 ASD 19 350 F Caucasian 22 4 167 24 14 n/a 6 3 
797 ASD 9 100 M Caucasian 13 17 178 24 20 13 6 blank 
4899 ASD 14 126 M Caucasian 9 8 183 22 n/a 14 8 4 
5176 ASD 22 199 M African 
American 
18 6 224 25 13 13 7 5 
5115 ASD 46 135 M Caucasian 29 6 358 27 n/a 14 8 1 









Table 3.2. Quality control metrics of whole-exome sequence data from paired samples as reported by CIDR. 
TARGET TERRITORY is the size of the exome-capture target. PCT PF UQ READS ALIGNED is the number of unique reads 
passing vendor quality filters that were successfully aligned to the genome. MEAN TARGET COVERAGE is the mean coverage over 



























1349_brain 36796199 72883652 0.976 71.6 0.0061 0.97 0.92 0.83 290 
1349_kidney 36796199 104449644 0.966 97.6 0.0053 0.98 0.96 0.91 291 
4722_brain 36796199 115826574 0.973 107.3 0.0052 0.98 0.96 0.93 294 
4722_heart 36796199 80539102 0.973 76.8 0.0063 0.97 0.93 0.86 299 
4671_brain 36796199 100995106 0.971 91.9 0.0071 0.97 0.95 0.89 304 
4671_heart 36796199 116486392 0.973 141.4 0.0077 0.98 0.95 0.92 208 
4849_brain 36796199 82153876 0.956 72.2 0.0055 0.98 0.92 0.84 307 
4849_heart 36796199 80847910 0.971 70.7 0.0054 0.97 0.92 0.84 300 
4907_brain 36796199 76114756 0.974 71.7 0.0067 0.97 0.92 0.83 299 
4907_heart 36796199 102900278 0.973 100.1 0.0062 0.98 0.95 0.91 289 
4999_brain 36796199 77877604 0.976 75.2 0.0056 0.98 0.93 0.85 307 
4999_heart 36796199 103195310 0.976 100.8 0.0052 0.98 0.96 0.92 296 
5144_brain 36796199 93790024 0.969 88.5 0.0058 0.98 0.94 0.89 295 
5144_heart 36796199 85663888 0.973 78.7 0.0052 0.98 0.94 0.87 308 
5278_brain 36796199 97717988 0.974 95.7 0.0066 0.98 0.95 0.91 288 
5278_kidney 36796199 89999006 0.973 82.5 0.0063 0.98 0.94 0.88 306 

































5391_heart 36796199 84728178 0.973 82.2 0.0053 0.98 0.94 0.87 290 
5408_brain 36796199 97274040 0.972 91.9 0.0052 0.98 0.95 0.90 297 
5408_heart 36796199 99165538 0.955 88.3 0.0054 0.98 0.95 0.89 298 
5419_brain 36796199 106813158 0.976 101.1 0.0067 0.98 0.96 0.92 300 
5419_heart 36796199 99144944 0.974 89.7 0.0065 0.98 0.95 0.90 309 
4889_brain 36796199 124350560 0.971 161.0 0.0078 0.97 0.94 0.90 169 
4889_heart 36796199 106054250 0.975 109.0 0.0053 0.98 0.96 0.92 253 
5115_brain 36796199 117191886 0.968 106.4 0.0048 0.98 0.96 0.93 301 
5115_heart 36796199 58995338 0.977 58.6 0.0061 0.97 0.89 0.77 283 
5179_brain 36796199 55503602 0.970 52.9 0.0062 0.96 0.87 0.74 296 
5179_heart 36796199 78292648 0.975 100.4 0.0076 0.97 0.92 0.87 180 
5403_brain 36796199 101087994 0.974 95.6 0.0050 0.98 0.96 0.91 287 
5403_heart 36796199 102836624 0.974 97.0 0.0050 0.98 0.96 0.91 279 
797_brain 36796199 149786604 0.971 173.2 0.0063 0.98 0.97 0.95 207 
797_heart 36796199 104011488 0.971 115.2 0.0060 0.98 0.96 0.92 225 




3.2.2 Paired sample tissue-specific variant calling 
Tissue-specific variants were called from paired samples using MuTect 2.7-1 for 
SNV discovery and Strelka 1.0.13 for indel discovery [132,133]. Input to these programs 
requires specifying a “tumor” and a “normal” sample. For each paired sample, variants were 
called twice so that mosaic variants were identified in both the brain and heart/kidney tissue. 
Validation of these variant calls was performed as indicated in Table 3.3 (run 1), with 








Table 3.3. Amplicon-targeted sequencing of potential tissue-specific variants in paired samples. 
Sample 
Run 
Number Chromosome Position Ref Alt Total_depth Variant_reads Percent_variants 
1349B 1 3 123376027 C T 8125 36 0.004430769 
1349K 1 3 123376027 C T 8098 36 0.004445542 
4671B 1 3 123376027 C T 8121 51 0.006280015 
4671H 1 3 123376027 C T 8116 49 0.006037457 
4671K 1 3 123376027 C T 8115 31 0.003820086 
4722B 1 3 123376027 C T 8117 50 0.006159911 
4722H 1 3 123376027 C T 8120 38 0.004679803 
4722K 1 3 123376027 C T 1 0 0 
4849B 1 3 123376027 C T 8121 28 0.003447851 
4849H 1 3 123376027 C T 8125 44 0.005415385 
4899B 1 3 123376027 C T 8119 52 0.00640473 
4899H 1 3 123376027 C T 8113 41 0.005053618 
4907B 1 3 123376027 C T 8116 39 0.004805323 
4907H 1 3 123376027 C T 8121 39 0.004802364 
4907K 1 3 123376027 C T 8119 38 0.004680379 
4999B 1 3 123376027 C T 8120 45 0.005541872 
4999H 1 3 123376027 C T 8110 45 0.005548705 
5115B 1 3 123376027 C T 8099 38 0.004691937 
5115K 1 3 123376027 C T 0 0 0 
5144B 1 3 123376027 C T 8113 33 0.004067546 
5144H 1 3 123376027 C T 8120 49 0.006034483 
5155H 1 3 123376027 C T 8129 27 0.003321442 
5176B 1 3 123376027 C T 8111 43 0.005301442 
5176H 1 3 123376027 C T 8099 39 0.004815409 









Number Chromosome Position Ref Alt Total_depth Variant_reads Percent_variants 
5278K 1 3 123376027 C T 8111 46 0.005671311 
5391B 1 3 123376027 C T 8110 32 0.003945746 
5391H 1 3 123376027 C T 8111 35 0.004315128 
5403B 1 3 123376027 C T 8110 19 0.002342787 
5408B 1 3 123376027 C T 8119 44 0.005419387 
5408H 1 3 123376027 C T 0 0 0 
5419B 1 3 123376027 C T 8119 36 0.004434044 
5419H 1 3 123376027 C T 8120 36 0.004433498 
797B 1 3 123376027 C T 8120 41 0.005049261 
797H 1 3 123376027 C T 8114 37 0.00456002 
1349B 1 10 79397364 C T 0 0 0 
1349K 1 10 79397364 C T 0 0 0 
4671B 1 10 79397364 C T 0 0 0 
4671H 1 10 79397364 C T 0 0 0 
4671K 1 10 79397364 C T 0 0 0 
4722B 1 10 79397364 C T 0 0 0 
4722H 1 10 79397364 C T 0 0 0 
4722K 1 10 79397364 C T 0 0 0 
4849B 1 10 79397364 C T 0 0 0 
4849H 1 10 79397364 C T 0 0 0 
4899B 1 10 79397364 C T 0 0 0 
4899H 1 10 79397364 C T 0 0 0 
4907B 1 10 79397364 C T 0 0 0 
4907H 1 10 79397364 C T 0 0 0 
4907K 1 10 79397364 C T 0 0 0 
4999B 1 10 79397364 C T 0 0 0 









Number Chromosome Position Ref Alt Total_depth Variant_reads Percent_variants 
5115B 1 10 79397364 C T 0 0 0 
5115K 1 10 79397364 C T 0 0 0 
5144B 1 10 79397364 C T 0 0 0 
5144H 1 10 79397364 C T 0 0 0 
5155H 1 10 79397364 C T 0 0 0 
5176B 1 10 79397364 C T 0 0 0 
5176H 1 10 79397364 C T 0 0 0 
5278B 1 10 79397364 C T 0 0 0 
5278K 1 10 79397364 C T 0 0 0 
5391B 1 10 79397364 C T 0 0 0 
5391H 1 10 79397364 C T 0 0 0 
5403B 1 10 79397364 C T 0 0 0 
5408B 1 10 79397364 C T 0 0 0 
5408H 1 10 79397364 C T 0 0 0 
5419B 1 10 79397364 C T 0 0 0 
5419H 1 10 79397364 C T 0 0 0 
797B 1 10 79397364 C T 0 0 0 
797H 1 10 79397364 C T 0 0 0 
1349B 1 15 28370205 T G 6648 139 0.020908544 
1349K 1 15 28370205 T G 6541 630 0.096315548 
4671B 1 15 28370205 T G 6545 151 0.023071047 
4671H 1 15 28370205 T G 6852 303 0.044220665 
4671K 1 15 28370205 T G 6757 255 0.037738641 
4722B 1 15 28370205 T G 6773 376 0.055514543 
4722H 1 15 28370205 T G 6663 155 0.023262795 
4722K 1 15 28370205 T G 0 0 0 









Number Chromosome Position Ref Alt Total_depth Variant_reads Percent_variants 
4849H 1 15 28370205 T G 6734 149 0.022126522 
4899B 1 15 28370205 T G 6609 294 0.044484793 
4899H 1 15 28370205 T G 6983 627 0.089789489 
4907B 1 15 28370205 T G 6781 372 0.054859165 
4907H 1 15 28370205 T G 6577 238 0.036186711 
4907K 1 15 28370205 T G 6606 245 0.037087496 
4999B 1 15 28370205 T G 6624 256 0.038647343 
4999H 1 15 28370205 T G 7018 679 0.096751211 
5115B 1 15 28370205 T G 6898 956 0.138590896 
5115K 1 15 28370205 T G 0 0 0 
5144B 1 15 28370205 T G 6837 482 0.070498757 
5144H 1 15 28370205 T G 6819 381 0.055873295 
5155H 1 15 28370205 T G 6747 158 0.023417815 
5176B 1 15 28370205 T G 6785 519 0.076492262 
5176H 1 15 28370205 T G 7062 703 0.099546871 
5278B 1 15 28370205 T G 6970 478 0.068579627 
5278K 1 15 28370205 T G 6849 486 0.070959264 
5391B 1 15 28370205 T G 6913 684 0.098944019 
5391H 1 15 28370205 T G 7020 646 0.092022792 
5403B 1 15 28370205 T G 6894 504 0.07310705 
5408B 1 15 28370205 T G 6853 409 0.059681891 
5408H 1 15 28370205 T G 0 0 0 
5419B 1 15 28370205 T G 6668 236 0.035392921 
5419H 1 15 28370205 T G 6645 221 0.033258089 
797B 1 15 28370205 T G 6628 240 0.036210018 
797H 1 15 28370205 T G 6875 443 0.064436364 









Number Chromosome Position Ref Alt Total_depth Variant_reads Percent_variants 
1349K 1 19 12772090 C T 11 1 0.090909091 
4671B 1 19 12772090 C T 12 11 0.916666667 
4671H 1 19 12772090 C T 10 10 1 
4671K 1 19 12772090 C T 29 25 0.862068966 
4722B 1 19 12772090 C T 25 0 0 
4722H 1 19 12772090 C T 9 1 0.111111111 
4722K 1 19 12772090 C T 0 0 0 
4849B 1 19 12772090 C T 43 19 0.441860465 
4849H 1 19 12772090 C T 16 12 0.75 
4899B 1 19 12772090 C T 11 7 0.636363636 
4899H 1 19 12772090 C T 13 6 0.461538462 
4907B 1 19 12772090 C T 16 9 0.5625 
4907H 1 19 12772090 C T 19 9 0.473684211 
4907K 1 19 12772090 C T 8 6 0.75 
4999B 1 19 12772090 C T 13 8 0.615384615 
4999H 1 19 12772090 C T 17 10 0.588235294 
5115B 1 19 12772090 C T 17 0 0 
5115K 1 19 12772090 C T 0 0 0 
5144B 1 19 12772090 C T 15 15 1 
5144H 1 19 12772090 C T 8 8 1 
5155H 1 19 12772090 C T 31 1 0.032258065 
5176B 1 19 12772090 C T 8 0 0 
5176H 1 19 12772090 C T 12 1 0.083333333 
5278B 1 19 12772090 C T 3 3 1 
5278K 1 19 12772090 C T 5 5 1 
5391B 1 19 12772090 C T 4 1 0.25 









Number Chromosome Position Ref Alt Total_depth Variant_reads Percent_variants 
5403B 1 19 12772090 C T 10 0 0 
5408B 1 19 12772090 C T 5 0 0 
5408H 1 19 12772090 C T 0 0 0 
5419B 1 19 12772090 C T 13 0 0 
5419H 1 19 12772090 C T 24 0 0 
797B 1 19 12772090 C T 11 10 0.909090909 
797H 1 19 12772090 C T 20 20 1 
1349B 1 19 49926533 G C 8001 217 0.02712161 
1349K 1 19 49926533 G C 1998 67 0.033533534 
4671B 1 19 49926533 G C 3768 129 0.034235669 
4671H 1 19 49926533 G C 2056 67 0.032587549 
4671K 1 19 49926533 G C 3553 123 0.034618632 
4722B 1 19 49926533 G C 4066 139 0.034185932 
4722H 1 19 49926533 G C 3600 132 0.036666667 
4722K 1 19 49926533 G C 0 0 0 
4849B 1 19 49926533 G C 4255 139 0.03266745 
4849H 1 19 49926533 G C 3514 124 0.035287422 
4899B 1 19 49926533 G C 2611 78 0.029873612 
4899H 1 19 49926533 G C 1558 41 0.026315789 
4907B 1 19 49926533 G C 4218 114 0.027027027 
4907H 1 19 49926533 G C 3163 89 0.028137844 
4907K 1 19 49926533 G C 3432 87 0.02534965 
4999B 1 19 49926533 G C 6129 187 0.030510687 
4999H 1 19 49926533 G C 1847 49 0.026529507 
5115B 1 19 49926533 G C 2628 86 0.032724505 
5115K 1 19 49926533 G C 0 0 0 









Number Chromosome Position Ref Alt Total_depth Variant_reads Percent_variants 
5144H 1 19 49926533 G C 2055 55 0.02676399 
5155H 1 19 49926533 G C 7090 193 0.027221439 
5176B 1 19 49926533 G C 2277 82 0.036012297 
5176H 1 19 49926533 G C 1913 42 0.021955044 
5278B 1 19 49926533 G C 3657 117 0.031993437 
5278K 1 19 49926533 G C 3779 112 0.02963747 
5391B 1 19 49926533 G C 3078 74 0.024041585 
5391H 1 19 49926533 G C 2200 69 0.031363636 
5403B 1 19 49926533 G C 2898 78 0.026915114 
5408B 1 19 49926533 G C 4385 104 0.023717218 
5408H 1 19 49926533 G C 0 0 0 
5419B 1 19 49926533 G C 4108 120 0.029211295 
5419H 1 19 49926533 G C 4319 133 0.030794165 
797B 1 19 49926533 G C 2863 88 0.030736989 
797H 1 19 49926533 G C 1874 61 0.032550694 
1349B 2 9 131020812 C A 1993 52 2.542787286 
4907K 2 9 131020812 C A 328 282 46.2295082 
5408K 2 9 131020812 C A 658 628 48.83359253 
4907H 2 9 131020812 C A 1860 15 0.8 
5419H 2 4 93225845 G T 52469 330 0.625011837 
4671H 2 4 93225845 G T 42184 182 0.429589765 
5419B 2 4 93225845 G T 53867 299 0.552006794 
4999H 2 13 113742714 G A 55469 197 0.353896454 
1349B 2 13 113742714 G A 373 5 1.322751323 
5419H 2 11 47600657 C T 43378 192 0.440670186 
5176K 2 11 47600657 C T 44861 145 0.322179265 









Number Chromosome Position Ref Alt Total_depth Variant_reads Percent_variants 
5176B 2 11 47600657 C T 24628 73 0.295534594 
4671H 2 11 47600657 C T 25866 73 0.281429508 
5408K 2 11 47600657 C T 28463 108 0.37800567 
4899H 2 11 47600657 C T 31216 106 0.33842028 
5419B 2 11 47600657 C T 26031 113 0.432221542 
5176H 2 11 47600657 C T 35327 118 0.332910142 
4722H 2 7 56149352 G A 23996 28 0.116550117 
5419K 2 7 56149352 G A 13492 27 0.199718914 
797H 2 1 151238513 C T 58590 118 0.200994754 
4849H 2 1 151238513 C T 32627 76 0.232394582 
4849K 2 1 151238513 C T 23183 67 0.288172043 
5722H 2 17 74271953 C T 22717 116 0.508036614 
797K 2 17 74271953 C T 4529 35 0.766871166 
4722K 2 17 74271953 C T 16932 80 0.47025629 
5176K 2 16 67289691 G A 47167 108 0.228450555 
5176B 2 16 67289691 G A 40377 93 0.229799852 
5115H 2 12 123950169 G A 61580 196 0.317275317 
4671K 2 12 123950169 G A 42831 104 0.242226622 
4671B 2 12 123950169 G A 31102 315 1.002641882 
4671B 2 12 123950169 G A 69022 151 0.218293265 
4671H 2 12 123950169 G A 52956 249 0.468001128 
4671K 2 12 123950169 G A 39577 69 0.174040256 
5176K 2 22 39811081 G A 332 1 0.3003003 
5419H 2 22 39811081 G A 70283 197 0.279511918 
5391K 2 22 39811081 G A 52660 97 0.183861857 
5391K 2 22 39811081 G A 52916 82 0.15472282 









Number Chromosome Position Ref Alt Total_depth Variant_reads Percent_variants 
5419H 2 16 426147 G A 391 1 0.255102041 
5144H 2 16 426147 G A 38942 80 0.205012557 
5419K 2 16 426147 G A 52727 64 0.121232786 
797K 2 7 116955170 ATCCTT A 34412 279 0.804243175 
5403K 2 7 116955170 ATCCTT A 28513 207 0.720752089 
5115K 2 7 116955170 ATCCTT A 30198 213 0.700404459 
5144B 2 7 116955170 ATCCTT A 45784 395 0.855367158 
5144H 2 7 116955170 ATCCTT A 516 3 0.578034682 
5278B 2 7 116955170 ATCCTT A 56898 416 0.725826151 
5408K 2 7 116955170 ATCCTT A 30900 198 0.636696894 
5278K 2 7 116955170 ATCCTT A 24550 159 0.643490226 
4899B 2 7 116955170 ATCCTT A 7426 50 0.668806849 
4899H 2 7 116955170 ATCCTT A 49376 362 0.727813744 
5176H 2 7 116955170 ATCCTT A 44270 289 0.648578289 
4899K 2 7 116955170 ATCCTT A 36772 232 0.626959248 
797B 2 7 116955170 ATCCTT A 37251 228 0.608340671 






To more carefully examine the properties of the mosaic variants called by MuTect, 
variants were recalled jointly in all samples using the GATK’s HaplotypeCaller in the 
“GENOTYPE_GIVEN_ALLELES” mode [235,236]. These variant calls were converted to a 
text based file format (Table 3.4) and allelic noise was annotated as an additional quality 
metric. Allelic noise was measured as the fraction of reads supporting the alternate allele 
relative to the total number of reads in all samples genotyped as homozygous for the 
reference allele by the HaplotypeCaller. Samples with called somatic variants were excluded 
from the calculations of allelic noise. If multiple alternate alleles were present, only the 
highest alleleic noise was recorded. Using allelic noise and the quality metrics annotated by 
the GATK’s HaplotypeCaller, the overall quality of the variants was assessed manually. 
Validation of the highest quality variants was attempted and the results of the validation are 








Table 3.4. Tissue-specific mosaic SNVs identified by MuTect. 
Quality metrics for each mutation are shown (n = 284). The “Called” column indicates samples in which the mutation was identified 
by a germline variant caller. For each mutation, the total number of sequence reads (DP) and the number of reads supporting the 
alternate allele (AD) are reported for each individual. Attempted validation of variants by targeted sequencing (orange), or both 
pyrosequencing and targeted sequencing (green) are indicated. Samples from brain (B), heart (H), or kidney (K) are noted as in Table 
3.1. 












1349B 1 1431165 C T TRUE 56.52 -5.16 -1.82 3.01 0 0.04 
4907B 5144H 1 6505917 A G TRUE 56.28 -5.76 3.3 -3.72 0 3.2 
4999B 1 16357117 A G FALSE 56.31 -5.17 -2 -0.85 0 4.89 
4671H 1 17085872 A G TRUE 51.13 -17.29 -9.54 -1.8 18.44 4.88 
4671B 1 22304463 A G TRUE 35.61 -2.71 21.03 1.35 0 0.67 
4999H 1 26671339 A C FALSE 58.97 -1.42 -8.33 3.4 9.15 6.99 
5408B 1 26671658 G A TRUE 58.89 0.41 -5.78 -1.94 6.68 2.09 
5115B 1 43166630 G A TRUE 58.97 -5.99 3.02 4.4 0 5.13 
5144B 1 109792751 T C TRUE 61.56 -1.45 -2.68 1.48 0 0.76 
5144H 1 120539742 G A TRUE 49 -6.92 2.54 2.82 4.79 5.35 
1349K 4722H 1 120612043 G T TRUE 49.72 4.95 -2.02 3.65 9.26 1.62 
5408H 1 145209116 T C FALSE 43.17 -5.25 1.63 -1.63 15.54 0.45 
4899B 1 145209191 G C FALSE 49.79 -5 3.07 -4.58 0 0.68 



















5408B 1 152278049 A C TRUE 33.71 5.93 10.41 1.94 19.73 4.63 
797H 1 152883347 C G FALSE 58.81 0.37 -6.69 -2.9 25.25 4.29 
5408H 1 155187144 A G TRUE 37.56 0.51 -3.06 1.02 0 4.17 
5419H 1 155292776 G C FALSE 57.35 1.92 -12.48 6.04 73.23 8.63 
5176H 1 155733245 C T FALSE 58.26 -12.47 -1.59 -12.83 6.32 0.25 
4899H 1 162773301 G A TRUE 50.07 -5.58 2.15 -3.58 4.24 5.55 
4907H 1 162775267 C T TRUE 49 1.98 -17.83 0.47 0.66 0.8 
5176B 1 186276588 T C FALSE 53.36 3.03 -16.16 -2.48 0.76 0.87 
5176B 1 196759282 C T TRUE 33.39 7.09 -1.59 0.84 8.47 2.92 
4722H 797H 1 243333027 A G TRUE 44.15 -5.61 13.42 0.95 18.4 9.72 
5408H 1 248085149 C G TRUE 49.98 -3.42 -1.3 1.63 2.93 0.29 
4671H 2 27324340 G A TRUE 59.65 
   
0 0.52 
5144H 2 48757264 C G TRUE 56.29 -3.78 1.62 0.38 0 1.59 
5176H 2 73901980 G A TRUE 59.07 -4.96 -4.53 -4.38 0 0.05 
4899H 2 96619734 C T TRUE 54.7 -11.02 -4.22 1.94 0 0.91 
4899B 2 96688929 G A TRUE 38.81 -10.11 5.39 -4.67 0 0.31 
4899H 2 130897234 C T TRUE 50.7 1.23 6.5 2.4 1.23 0.8 
4849B 2 130900091 C T FALSE 45.56 -1.49 -2.1 -0.37 0 1.06 
5278K 2 132110862 G C FALSE 35.17 1.87 -1.02 1.13 67.46 4.09 
4849B 2 132229694 C T FALSE 49.88 -2.94 -1.07 -1.63 0 0.68 
5176H 2 132236921 G A TRUE 55.49 -13.16 9.83 4.05 2.55 5.12 
4999H 2 171627348 G C FALSE 56.04 0.98 -2.45 2.68 86.15 5.54 
4722B 2 171627363 A C FALSE 57.54 0.81 -13.9 -3.96 2.32 3.07 



















5176H 2 198363501 C T TRUE 59.05 -1.69 -1.5 -1.56 0 1.43 
5176B 2 200684266 C A FALSE 59.35 0.75 -6.4 1.53 0 3.3 
5144B 2 207911121 A G FALSE 39.1 1.33 -1.49 -1.21 0 0.03 
5176H 2 234590616 C A TRUE 58.89 -1.19 -1.74 0.67 6.35 0.83 
1349B 4671B 
5176B 5115B 
4899H 3 10114944 A C TRUE 57.85 -17.26 4.84 4.46 2.17 4.96 
4899H 3 42700630 A G TRUE 59.22 0.33 -14.02 4.48 2.04 0.51 
4849B 3 49724808 T C TRUE 56.57 -1.81 -4.56 0.95 0 0.66 
5176B 3 65425591 T C TRUE 60.33 -0.97 -2.31 1.2 0 0.88 
5176B 3 65425594 C T FALSE 60.3 -0.49 -1.23 -0.41 0 1.4 
5176B 3 123376027 T C FALSE 59.51 -1 -0.89 1.17 0 2.29 
1349K 3 132441084 C T FALSE 59.23 0.8 0.9 2.11 0 0.42 
4671B 3 195400728 A G TRUE 46.44 -9.22 -10.65 4.82 0 0.67 
5419B 5115H 4 4239589 C T TRUE 51.24 -10.22 -8.02 -2.12 23.18 6.87 
5419H 4 93225845 G T FALSE 59.68 1.13 -0.39 -1.94 0 1.54 
4849H 4 141771717 T G FALSE 57.73 
   
0 0.03 
797H 4 147824864 G A TRUE 59.6 0.54 1.93 5.73 0 0.45 
5408H 4 152024138 A C TRUE 47.81 -3.99 -4.65 -1.75 8.52 2.41 
5403H 4 153870322 A C TRUE 55.37 5.64 11.99 3.86 0 0.64 
5419B 5 94956735 C T FALSE 59.4 1.92 0.54 0.84 0 0.68 
5115B 5 104043367 A G FALSE 59.84 -1.72 -1.71 -0.29 0 0.36 
5115B 5 104043370 G A FALSE 59.82 0.47 -0.07 0.46 0 0.24 
5278K 5 139781730 G A FALSE 59.58 0.42 1.86 0.42 0 0.57 



















5419H 5 140050940 C T TRUE 52.9 -7.36 -3.86 2.17 0 0.94 
4907B 5 167988433 T A TRUE 58.16 -3.76 -2.02 0.36 2.53 0.13 
5176B 5 178949876 C T FALSE 38.17 0.01 0.06 2.48 13.64 8.01 
5176B 5 180431746 C T TRUE 56.24 -2.47 -0.45 1.23 0 1.43 
5403H 6 9616237 G A TRUE 54.18 4.79 0.24 -2.51 0 1.02 
5176H 6 10756728 C T TRUE 58.83 -1.37 2.05 0.04 0 2.22 
5391B 6 16327903 C A TRUE 60 -1.23 -2.44 3.68 0 1.18 
5144B 6 16327921 C A TRUE 60.18 
   
0 0.3 
4907H 5176H 6 27114569 T C FALSE 54.11 -5.12 2.85 -0.84 0 2.81 
4999B 6 29857360 G A FALSE 55.8 -10.25 2.14 4.37 2.55 0.34 
5403H 6 29912153 A G TRUE 53.99 -15.56 1.46 2.91 34.41 7.38 
5176B 6 31963559 A G TRUE 31.18 5.77 3.23 1.68 3.03 7.16 
4671H 6 31977552 C G TRUE 44.18 -5.53 0.97 -5.29 2.58 2.22 
4899B 6 32713674 C A TRUE 55.25 -15.6 -5.28 9.36 11.14 2.02 
4899B 6 32714091 A G TRUE 58.65 -10.36 -8.09 2.52 2.55 3.51 
4899H 6 44221048 T G FALSE 58.23 -18.31 4.96 -2.09 5.09 6.77 
5419B 6 51914982 C T FALSE 59.34 0.58 -2.02 0.08 0 0.44 
4999H 6 130504496 G A TRUE 55.96 1.28 -0.24 -0.95 1.14 0.84 
5419B 6 157100005 C A TRUE 59.4 0.21 5.46 0.45 0 2.64 
5115B 6 170871061 G A FALSE 60.91 -1.09 -1.73 -0.92 0 0.3 
5408B 7 1574061 A C FALSE 59.22 0.4 -22.23 4.02 25.02 6.45 
5419H 7 56149352 G A FALSE 59.42 -0.62 1.61 0.32 0 0.22 
5419H 7 72413896 A G TRUE 46.11 -6.94 6.02 -0.02 15.56 6.56 



















4899H 7 72419616 C A FALSE 45.86 -11.73 -5.92 6.48 33.73 10.28 
5278B 7 72420467 G A FALSE 49.94 -6.75 3.52 -4.97 0 1.09 
5391B 7 75028240 T C TRUE 27.74 -4.46 0.78 2.49 3.06 0.25 
5391B 7 75028241 G A TRUE 27.77 -4.79 -2.41 2.1 2.98 0.24 
5408B 7 82583018 A T FALSE 58.98 -0.23 -1.96 0.69 0 0.46 
4722B 4671H 
5278K 5391B 
5176H 7 99795228 G T TRUE 58.09 -15.22 -1.9 3.62 0 0.56 
5408B 7 100028822 G A FALSE 59.48 -0.34 -1.19 1.85 0 0.44 
4899H 7 141767225 C T TRUE 44.64 -2.16 5.14 0.7 0 0.55 
4671B 7 145691990 T C FALSE 57.42 
   
0 0.03 
4899H 7 151970945 G T FALSE 47.37 -1.89 -0.78 -2.2 0 0.62 
5115H 7 152513619 G A FALSE 36.73 4.44 10.01 0.8 21.59 10.49 
5278B 7 153750140 G A FALSE 56.86 -6.1 5.65 -2.79 4.57 1.24 
5176B 8 7274308 A G TRUE 30.32 11.79 7.99 2.38 102.35 8.47 
5176H 8 11188922 T C TRUE 57.62 -16.25 -5.89 -0.69 0 0.55 
4999H 8 143959174 T C TRUE 57.03 -8.62 0.79 0.3 6.55 0.14 
5115B 9 20414343 A G FALSE 58.56 1.24 -0.49 -0.76 0 0.77 
797H 4899H 9 34725438 A G TRUE 32.5 8.02 -8.52 -1.62 14.47 3.24 
4671B 9 34834814 C G FALSE 46.99 -12.46 2.66 0.92 0 1.09 
5176B 9 34834937 A G TRUE 42.72 -10.12 12.77 2.32 0.89 0.57 
4899H 9 34835480 C T FALSE 47.69 -8.44 11.35 -0.16 5.19 8.38 
5176B 9 66457019 G A TRUE 54.36 3.77 8.28 1.78 0 0.28 
4671B 4999H 9 66457216 A G TRUE 49.85 -7.47 5.12 -0.79 0 0.79 



















5115B 9 78790143 G A TRUE 57.76 2.7 -5.46 -2.84 0 0.44 
5403H 9 96439007 G T TRUE 55.1 
   
0 0.59 
5408B 9 130457371 A G FALSE 60.95 -3.01 0.39 -0.02 0 0.01 
4849H 9 130457374 G A FALSE 60.97 -0.59 -2.17 -0.75 0 0 
5408H 9 131020812 C A TRUE 59.37 0.67 -0.66 0.3 0 0.23 
4899H 9 137742628 G C FALSE 56.7 3.4 -15.33 -5.24 13.46 5.82 
4907H 4999B 10 21805480 T C TRUE 53.12 4.53 0.19 -0.19 2.22 1 
5115B 10 21806056 G A FALSE 57.76 5.06 13.86 3.49 0 0.35 
4671B 4907H 10 38647315 T C FALSE 55.99 -11.39 5.25 -1.12 0 5.43 
5176H 10 52502717 G A TRUE 54.84 -6.71 4.27 0.65 0 3.34 
797B 10 79397364 C T FALSE 58.77 -1.04 3.17 3.64 0 1.12 
4849B 10 99330268 A C FALSE 59.49 1.56 -21.33 6.25 35.8 8.96 
5419B 11 47600657 C T FALSE 59.32 -0.28 -1.09 1.5 0 0.55 
4907H 11 49208319 G A TRUE 57.54 -15.57 -3.63 -0.18 1.69 1.2 
4999B 11 55656479 T G FALSE 56.95 -5.9 -3.23 4.47 0 0.17 
4671B 11 56468111 C T TRUE 48.76 -5.97 -1.38 3.05 5.56 6.02 
4849H 4999H 
5115B 11 89531764 T C TRUE 44.33 -5.47 -1.24 -2.25 0 0.84 
4899H 11 95825221 C T FALSE 59.22 -0.61 -5.19 1.13 0 1.07 
5176B 11 95825407 C T TRUE 60.14 -0.24 -1.29 -0.15 0 1.44 
4907H 11 117073821 T G TRUE 59.49 -0.29 -19.22 4.44 18.99 8.5 
5176B 11 117789345 G C TRUE 60.05 0.86 -1.43 -1.72 0 1.43 
797B 12 2039173 A G TRUE 55.59 1.81 -4.88 0.16 0 0.03 



















4899H 12 9447061 C T TRUE 38.15 -0.22 6.39 0.92 4.88 5.9 
5391H 12 9573223 C A TRUE 43.95 -2.95 -11.49 2.39 2.73 0.51 
5176H 12 11506749 T C FALSE 48.26 -23.2 12.39 1.49 11.23 1.05 
5408H 12 13153153 C T FALSE 57.89 
   
0 0.06 
797B 12 13153397 G C TRUE 51.96 
   
0 0.05 
5144H;797H 12 21623127 A G FALSE 43.19 -3.64 8.1 1.31 0 3.92 
5278B 12 31244665 C T TRUE 47.89 -2.38 -1.99 -0.85 0 0.17 
5278B 12 31244703 C T FALSE 47.42 -20.41 6.56 -7.61 24.36 1.45 
5176H 12 31244784 C A FALSE 52.89 -6.05 1.89 -3.08 0 1.38 
4849H 12 31255198 G A FALSE 51.71 -2.31 2.21 2.43 0 0.39 
5419B 12 31255209 G A FALSE 52.3 -11.27 -5.84 5.06 0 4 
5419B 12 49213447 G A FALSE 59.4 -0.01 -1.02 -1.13 0 0.13 
5144B 5391B 
5419H 12 49427679 C T FALSE 59.55 -1.3 -5.86 1.14 0 0.84 
5115B;5176H 12 52699548 T C TRUE 55.52 -19.2 -29.46 -0.66 5.05 1.12 
4671H;5278B 12 53298675 A C FALSE 56.13 -11.37 6.78 -3.27 9.54 2.02 
4671H 12 53298699 G A TRUE 54.06 -11.75 5.55 7.39 6.64 2.27 
4999H 12 53345343 G A FALSE 59.36 0 -2.03 -0.38 0 0.51 
5403H 12 57112377 A G FALSE 58.74 0.22 -8.53 -0.28 4.25 1.42 
5408B 12 63964599 T C FALSE 57.24 -15.63 0.68 -3.58 0 0.51 
5408B 12 63964600 G A FALSE 57.21 -15.25 -7.48 -3.73 0 0.47 
4671B 12 123950169 G A FALSE 59.46 0.32 1.49 0.33 0 1.24 
5278K 12 132547087 G A TRUE 60.82 -1.07 -2.52 -0.01 0 0.77 
4849B 5144B 



















4671B 12 132589038 A G FALSE 32.25 3.72 3.57 1.59 9.24 6.09 
5144B 13 20066994 T C TRUE 46.76 -14.92 9.26 -9.06 11.58 0.88 
4899H 13 24895393 A G TRUE 42.14 -13.94 17.06 0.49 33.59 3.6 
4722B 13 25016762 G A TRUE 58.27 -7.56 -6.26 -1.68 14.54 2.99 
5419B 13 25021201 G A TRUE 49.16 -10.28 6.21 5.67 18.44 4.49 
5176H 13 25052393 G T TRUE 57.78 -11.43 -5.04 3.92 4.57 0.89 
1349K 13 32818263 G A FALSE 59.48 -0.2 2.53 0.12 0 1.07 
5419B 4899B 13 45523879 T C FALSE 58.97 -3.25 -5.02 -2.72 0 0.01 
1349K 13 113742714 G A FALSE 59.67 -0.1 -2.12 -0.54 0 0.51 
4671B 14 19685516 C T FALSE 26.23 2.77 -1.87 -0.29 5.95 1.25 
5278B 14 23744826 T A TRUE 61.91 
   
0 0.04 
5278B 14 23744829 C T TRUE 61.88 -1.04 1.64 0.43 0 0.14 
4671H 14 70924335 C T TRUE 52.22 -5.2 3.5 -0.67 0 3.07 
1349B 5391B 
5176H 14 70924450 C T TRUE 49.77 -13.69 -10.78 -1.19 1 0.48 
5176B 14 74008216 C G TRUE 55.13 -6.21 -3.24 1.07 0 3.39 
5176B 14 74008309 C T TRUE 55.78 -7.8 -5.43 -0.08 4.12 1.34 
5176B 14 106053577 A G TRUE 37.55 1.22 1.11 0.55 12.93 2.23 
4849B 14 106436096 C T TRUE 59.24 -1.49 -1.58 0.28 0 0.34 
5176B 14 106518415 C A TRUE 41.63 -1.94 -4.32 -0.56 0 1.4 
5176H 14 106691691 A G FALSE 38.41 -2.6 -3.1 -0.09 0 0.32 
4849B 15 20454011 G A TRUE 52.15 -5.71 -2.67 2.25 3.19 5.13 
4722B 15 20462613 G C TRUE 55.01 7.23 -7.01 1.25 1.25 0.45 



















4849B 15 22413810 G C FALSE 52.43 -5.72 0.4 -3.69 0 0.91 
5403B 15 28370205 T G FALSE 59.33 0.44 -22.9 12.14 40.95 8.85 
4722H 15 28474439 C T FALSE 44.63 1.6 2.63 0.09 0 0.02 
5403H 15 28501283 T G FALSE 58.75 -0.71 -16.06 -1.59 15.32 6.39 
4722B 5391B 15 29009175 G A TRUE 50.07 -7.08 2.85 5.02 10.76 7.22 
4899H 15 29009243 G A FALSE 49.93 -9.7 -3.16 2.04 26.08 8.53 
5403H 15 44487184 C T FALSE 59.59 -0.21 -2.14 1.45 0 0.47 
1349K 15 50784955 C A TRUE 59.07 -14.28 -5.26 -1.12 0 0.77 
5408H 15 90320161 G A TRUE 58.4 1.61 -0.54 -0.4 0 0.22 
4899H 15 90320173 A G TRUE 58.53 
   
0 0.06 
5403H 15 100252741 A C TRUE 57.45 0.54 -0.58 1.14 0 3.78 
5419H 16 426147 G A FALSE 59.27 0.06 1.91 2.29 0 0.69 
5144B 16 1306918 C T TRUE 56.09 -11.56 10.25 3.24 0 0.7 
5144B 16 1306921 G A TRUE 56.14 -11.5 2.04 1.94 0 0.71 
5176H 16 4944518 C G TRUE 59.37 -2.15 4.23 0.32 0.74 0.79 
5144H 16 28603714 C T FALSE 58.18 -4.07 -2.46 -3.47 0 1.2 
5176H 16 32890639 T C TRUE 45.38 -6.44 -7.23 -9.81 21.67 3.58 
797B 16 33738633 G A FALSE 47.98 -5.68 3.69 -1.26 3.3 5.42 
4722H 5408H 16 65839631 T C TRUE 59.39 -1.58 -0.63 -1.7 0 1.42 
5176H 16 67289691 G A FALSE 59.33 0.21 1.29 1.21 0 1.07 
5115B 16 69996928 G A TRUE 37.7 -0.99 -1.35 2.86 0 3.4 
5419B 16 70154480 A G TRUE 56.61 -20.75 3.47 -4.72 4.02 1.11 
4671B 16 71103269 T C TRUE 40.42 -1.17 -1.05 0.68 0 4.37 



















5278K 16 72821609 G A FALSE 57.81 -1.41 -1.42 -1.43 0 1.47 
5278B 16 72821624 G A FALSE 57.42 0.35 0.86 0.25 0 0.4 
4999H 16 72992617 C T FALSE 59.15 
   
0 0.61 
4722B 16 74372644 A G FALSE 51.88 -10.38 -6.13 -1.27 3.01 1.91 
4849B 17 7466636 G A FALSE 59.36 1.13 -1.6 -0.58 0 1.27 
4899H 17 7843053 C T TRUE 59.5 0.18 -11.66 4.53 0 0.66 
4671B 4899H 17 18682505 T C TRUE 41.83 -9.24 6.17 1.62 1.13 0.99 
5115B 17 21199403 C T TRUE 55.7 -5.23 -1.51 0.48 0 0.62 
4899H 17 21202191 C A TRUE 58.33 -11.99 2.01 1.88 2.87 7.13 
4899B 17 39274087 G C TRUE 46.55 -9.29 -4.72 -3.1 9.15 0.81 
5391B 17 39274416 C T TRUE 57.65 -15.4 -2.91 -10.47 1.69 0.26 
5408H 17 39334314 A T TRUE 57.87 -4.38 -2.04 -0.06 0 0.9 
5419B 17 43317923 G A FALSE 59.48 -0.22 -1.46 1.04 0 0.82 
4899H 17 45127107 C G FALSE 45.18 -22.73 5.04 -1.18 9.04 7.76 
5278B 17 45664677 C T FALSE 44.39 -6.57 12.56 5.02 10.7 9.12 
5403H 17 56603934 A C TRUE 57.78 -1.99 1.7 -4.34 0 0.63 
4899H 17 71443848 C T TRUE 59.48 0.33 3.03 0.48 0 1.5 
4722H 17 74271953 C T FALSE 59.06 -0.59 0.72 0.77 0 0.54 
5278B 17 78064060 G A FALSE 56.28 
   
0 0.44 
4899H 18 9887493 T C TRUE 59.3 2.38 -12.7 -3.34 0 0.68 
4849H 18 14156352 A C FALSE 46.75 -3.75 5.54 2.58 2.6 4.98 
4849B 797H 18 61391468 C T TRUE 51.95 2.43 -2.32 -0.26 0 0.93 
4849B 19 1827059 A G FALSE 58.94 -1.28 -13.41 0.89 16.75 0.06 



















5419H 19 10752079 A C FALSE 58.89 -0.68 -0.13 0.3 0 0.17 
4999B 5419H 19 10752080 C A FALSE 58.94 2.23 -2.57 -5.61 1.91 0.24 
5115B 19 12772090 C T TRUE 59.51 -1.37 10.53 0.64 2.36 1 
5408B 19 14884843 C T TRUE 55.63 -2.81 -1.27 0.63 0 1.56 
5144B 19 16640583 C T FALSE 59.48 
   
0 0.21 
4999B 19 17006736 A G TRUE 55.75 -1.74 -6.33 4.57 0.79 0.77 
5115H 19 17397477 G T TRUE 57.31 1 -3.41 -0.23 3.77 1.59 
4999B 19 18879426 A C FALSE 58.81 0.41 -14.85 3.24 61.8 7.06 
5115B 19 22363844 G A TRUE 53.69 -0.39 -14.77 -16.75 11.75 1.43 
5391B 19 22585603 T C TRUE 53.54 -8.98 3.9 -5.62 0 0.91 
4907H 19 22836805 G A TRUE 52.5 -18.77 -9.14 -12.84 0 0.58 
5391H 19 33490585 G A TRUE 49.39 -9.15 -6.29 -0.73 6.65 1.49 
4849H 4907H 
4899B 19 33517507 C T FALSE 58.84 -7.62 -1.09 -5.16 2.96 4.14 
5391B 5403B 19 40376323 A G FALSE 34.51 -2.29 1.68 1.34 2.36 1.73 
4849H 19 41627496 C T TRUE 55.88 -3.69 -1.3 0.83 0 0.84 
5144B 19 43031434 T A TRUE 58.51 -15.03 1.56 -7.05 8 2.76 
4999H 19 48305574 A G FALSE 58.88 0.12 -11.63 1.66 7.19 1.75 
4849H 19 48305694 A G TRUE 58.6 2.16 -11.48 -1.14 4.95 0.3 
797B 19 49926533 G C TRUE 59.52 -0.44 -0.53 2.51 0 0.64 
4907H 19 50463670 T G TRUE 46.76 -1.34 22.54 6.24 3.99 1.07 
4671H 19 51274851 A C TRUE 53.42 -16.19 7.99 5.29 25.02 2.38 
4899B 19 52132668 T C TRUE 42.28 -0.72 3.64 2.87 12.07 3.15 




















5176B 19 53770304 T G TRUE 42.42 -4.35 -0.51 -1.79 2.3 4.45 
4899B 19 53788121 A G TRUE 49.4 -3.1 -2.04 0.64 0 3.23 
4907B 19 54723995 G C TRUE 43.21 -13.11 -10.04 -1.05 92.34 8.12 
4849H 19 54726237 C G TRUE 30.03 4 0.72 0.9 8.75 6.18 
5176B 19 54744128 A T FALSE 43.38 -2.91 -1.33 -2.22 0 0.11 
5176B 19 54744133 G A TRUE 43.49 -4.9 5.71 -0.42 0 0.27 
1349B 4671H 19 55324635 T C TRUE 53.41 -5.97 2.48 5.28 0 0.44 
5176H 19 58371368 T G TRUE 54.4 -6.46 4.75 2.4 0 5.76 
4671B 19 58421080 G T TRUE 29.96 12.98 -12.39 -0.98 4.75 1.09 
4907H 20 1585397 T C TRUE 42.92 -8.36 7.92 4.44 1.08 0.8 
4907H 20 1585446 G A TRUE 39.09 -7.53 7 -2.17 7.34 1.6 
5419H 20 26061803 C A TRUE 52.63 -13.89 -6.68 2.22 11.09 4.89 
5176H 21 11098729 G A FALSE 57.57 -0.27 -1 -2.21 0 0.74 
5419H 21 36410912 G C TRUE 47.25 6.92 -2.52 5.29 0 0.38 
4899H 21 46011298 G A TRUE 45.83 -4.94 -3.83 -0.86 15.81 7.17 
5278B 21 46011397 A G TRUE 51.95 -6.51 3.81 3.69 6.78 2.56 
5278B 21 46011400 G A FALSE 51.83 -5.71 1.27 2.98 6.82 6.09 
5278K 22 39357586 T C TRUE 41.58 -2.88 5.63 0.93 0 4.46 
5391H 22 39811081 G A TRUE 59.56 -0.47 1.73 0.87 0 0.9 
4671H 22 42523636 C A TRUE 56.47 -21.28 -10.15 -1.1 22.58 9.88 
4671H 22 42908976 G A TRUE 52.59 -5.21 1.5 1.58 3.6 1.73 
1349K 22 42911257 A G TRUE 38.72 -1.13 -9.96 3.38 103.89 9.75 
4849H 22 50315971 C G TRUE 57.85 




















4849H 22 50315973 G C TRUE 57.88 -0.68 8.32 5.32 1.31 0.84 
4722H X 18660190 C T FALSE 59.33 0.73 -2.63 -0.34 0 1.13 
5115H X 37028645 G C FALSE 56.12 3.43 -9.96 -1.02 6.13 2.35 
5176H 5115H X 51075901 G A TRUE 54.11 -13.66 -9.36 0.98 23.79 7.85 
4907H X 53652838 G A TRUE 55.76 -5.77 2.86 1.94 15.29 1.27 
4907H X 53652846 G T TRUE 56.22 -5.58 -3.09 -0.87 22.85 0.92 
4671H 4907H X 53652852 T G TRUE 56.88 4.17 4.21 -1.83 20.23 2.03 
5408H X 53966821 T A FALSE 59.46 -0.65 -0.79 2.7 0 1.03 
5144B 797H X 64956699 G A TRUE 57.73 -1.61 -0.8 1.15 0 0.53 
5144B 797H X 64956743 A G TRUE 58.03 -1.09 0.63 0.3 0 1.44 
4671B X 110987993 A T FALSE 59.16 -0.04 -1.59 -1.7 0 0.67 
5144H X 114425196 G A TRUE 45.36 
   
0 0.39 
5419B X 136649009 C T FALSE 59.41 -0.14 2.01 0.54 0 1.11 
            
Validation Legend: 
          
Targeted Sequencing 
          
Pyrosequencing and 
Targeted Sequencing 
          







Table 3.5. Pyrosequencing of potential tissue-specific variants in paired samples. 
Well Assay Sample ID 
Var. 









C1 NDUFS3 5419B R Passed   1.49 - 98.51 - 
C2 NDUFS3 5419H R Passed   1.59 - 98.41 - 
C3 NDUFS3 5419K R Passed   1.33 - 98.67 - 
C4 NDUFS3 5176B R Passed   1.66 - 98.34 - 
C5 NDUFS3 5176H R Passed   1.83 - 98.17 - 
C6 NDUFS3 5176K R Passed   0.75 - 99.25 - 
C7 Control Control Y Passed   - 53.73 - 46.27 
C8 Control Control Y Passed   - 52.51 - 47.49 
A1 GRID2 5419B K Passed 
 
- - 96 0 
A2 GRID2 5419H K Passed 
 
- - 95 2 
A3 GRID2 5419K K Passed 
 
- - 81 1 
A4 PHKG1 5419B K Passed 
 
- - 96 4 
A5 PHKG1 5419H K Check Uncertain due to low peak height. - - 91 9 
A6 PHKG1 5419K K Passed 
 
- - 94 6 
A7 SLC9A5 5716B Y Passed 
 
- 99 - 1 
A8 SLC9A5 5716H Y Passed 
 
- 99 - 1 
B1 SLC9A5 5716K Y Passed 
 
- 98 - 2 
B2 QRICH2 4722H R Passed 
 
3 - 97 - 
B3 QRICH2 4722K R Passed 
 
3 - 97 - 
B4 TAB1 5391B R Failed 
Failed due to low peak height. 
Uncertain surrounding reference 
sequence pattern. 9 - 91 - 
B5 TAB1 5391K R Check 
Uncertain surrounding reference 
sequence pattern. Uncertain due to 
low peak height. 7 - 93 - 
B6 SNRNP35 4722H R Passed 
 







Well Assay Sample ID 
Var. 









B7 SNRNP35 4722K R Passed 
 
2 - 98 - 
C7 Control Control Y Passed   - 47 - 53 





For visualization, the properties of variants including "BaseQRankSum", "FS", 
"MQ", "MQRankSum", "ReadPosRankSum" and "SOR" were examined in the Illumina 
Platinum Genomes (see below) and variants called by MuTect. These properties were 
collectively scaled, principal components analysis was performed and the original variant 
features were transformed into the principal components. 
3.2.3 In silico mixing experiment using NA12878 and NA12882 
200x sequence data from NA12878 and NA12882 were downloaded from EBI 
(ERP001775). The specific runs chosen were ERR174324, ERR174325, ERR174326, 
ERR174327, ERR174328, ERR174329, ERR174330, ERR174331, ERR174332, 
ERR174333, ERR174334, ERR174335, ERR174336, ERR174337, and ERR174338 for 
NA12878 and ERR174347, ERR174348, ERR174349, ERR174350, ERR174351, 
ERR174368, ERR174369, ERR174370, ERR174371, ERR174372, ERR174373, 
ERR174374, ERR174375, ERR174376, and ERR174377 for NA12882. Sequence data were 
aligned to the 1000 Genomes phase 2 human reference genome using BWA MEM version 
0.7.9a and aligned sequence reads were sorted using SAMtools [134,234]. Aligned sequence 
data were then combined into single files and in silico mixing with subsampling was 
performed using submixbam (https://github.com/DonFreed/submixbam) version 290fda over 











trace.ncbi.nih.gov/giab/ftp/data/NA12878/analysis/GIAB_integration/). A variant calling and 
pipeline was written using Snakemake [237]. This pipeline called variants from mixtures 
using the GATK’s HaplotypeCaller version 3.4-46. The sensitivity of the HaplotypeCaller 
for variants known to be present in NA12878 and absent from NA12882 was then evaluated 
using hap.py (https://github.com/Illumina/hap.py).  
3.2.4 Simons Simplex Collection Analysis 
Analysis of the data in the Simons Simplex Collection made use of cloud computing 
via Amazon Web Services (AWS) for variant calling (GATK HaplotypeCaller), merging 
gVCFs (GATK MergeGVCFs) and genotyping (GATK GenotypeGVCFs). Starcluster 
(http://star.mit.edu/cluster/) was used for deployment and configuration of clusters of virtual 
machines on AWS Elastic Cloud Compute (EC2) and a customized Amazon Machine Image 
(AMI) was created containing GATK 3.5-0, samtools 1.2, Python 3.5.1, and 
nda_aws_token_generator version 20b72 
(https://github.com/NDAR/nda_aws_token_generator) [134,235,236]. c3.xlarge, r3.xlarge 
and r3.2xlarge instances were used for variant calling, merging gVCFs and genotyping, 
respectively. During variant calling and merging, the available disk space on each node was 
used as a complex resource to aid in job allocation. With c3.xlarge instances, ephemeral 
storage partitions were combined into single logical volumes using RAID 0. During 
genotyping, node ephemeral disk partitions were combined into a single network attached 
storage volume using GlusterFS (https://www.gluster.org/).  
3.2.5 Simons Simplex Collection variant discovery 
Aligned whole-exome sequence data from 8,950 individuals in the SSC was accessed 




Simple Storage Service (AWS S3) (https://ndar.nih.gov/study.html?id=334). We excluded 16 
individuals from families 11366, 11368, 11377 and 11380 due to data processing issues. 
Variants were called using the GATK (v. 3.5-0) HaplotypeCaller in gVCF mode with 
standard variant annotations and additional arguments -ploidy 5, -A GCContent and –A 
AlleleBalance over NimbleGen EZ-SeqCap v2.0 targets with 50 bp of padding [235,236]. 
gVCFs of 20 families were combined using GATK MergeGVCFs resulting in 120 merged 
gVCF files. All gVCF files were genotyped across capture regions in parallel using the 
GATK GenotypeGVCFs command with the arguments -stand_call_conf 25.0, -
stand_emit_conf 20.0 along with the arguments used with the HaplotypeCaller as described 
above. The genotyping step had high memory requirements over some target regions, causing 
some jobs to fail even with 116 GB of memory allocated to the java virtual machine. Failed 
capture regions were repeated with the additional argument --max_alternate_alleles 5. 
However, we excluded 53 capture targets due to persistent memory errors (Table 3.6). These 
capture targets were highly enriched for overlap with known simple repeats (UCSC Simple 
Repeats Track in BED format; tested using BEDtools fisher; Fisher’s Exact Test, p < 
0.00001). Variant calls over each capture target were then concatenated and duplicate calls 






Table 3.6. Capture targets excluded due to extremely high memory usage. 
  
Chrom Start Stop 
1 6192855 6192955 
1 25362447 25362597 
1 38332122 38332223 
1 207237096 207237196 
2 119748137 119748237 
2 192225356 192225455 
3 8671331 8671431 
3 38355217 38355432 
3 38627181 38627532 
3 75790760 75790887 
3 186302218 186302378 
3 195505661 195518368 
4 82013523 82013623 
4 88534936 88537720 
5 149583229 149583342 
5 153085256 153085627 
5 167995650 167996003 
6 31380102 31380237 
6 32485472 32485572 
6 32546824 32546924 
7 286376 286477 
7 123190523 123190640 
7 151552452 151552633 
8 10464404 10470856 
9 8331581 8331736 
9 136637074 136637174 
10 3208421 3208572 
10 12142168 12142269 
10 135103327 135103473 
10 135438602 135439108 
11 1015761 1018770 
11 10823595 10823756 
11 60778524 60778624 
11 71238346 71238844 
11 85979497 85979603 




12 53207380 53208064 
14 39783923 39784023 
14 81574707 81574807 
14 81574893 81575030 
14 92537278 92537397 
15 52548826 52548926 
16 9017071 9017270 
16 33965500 33965600 
16 89178499 89178654 
17 2297569 2297669 
19 5787071 5787182 
19 48613708 48613808 
20 54963182 54963282 
20 56236685 56237090 
21 40717071 40717200 
21 42551103 42551555 
22 32827317 32827417 




3.2.6 Simons Simplex Collection variant filtration 
In addition to the variant annotations produced by the GATK, raw variants were 
annotated with the number of sequencing reads supporting the reference allele relative to 
total number of sequence reads. This information was added to the VCF’s INFO field as the 
annotation “AbHetUser”. Variants were filtered using the GATK variant quality score 
recalibration pipeline. The recommended parameters for whole-exome sequencing were used 
minus the –an QD parameter and with the additional parameter –an AbHetUser. These 
parameters were chosen for their superior sensitivity and specificity for validated de novo 
variants in the SSC. SNPs were filtered with a sensitivity tranche of 99.3% while indels were 
filtered with a sensitivity tranche of 98%.  
3.2.7 Simons Simplex Collection de novo and mosaic variant identification 
De novo variants were identified using the tool find_denovo, a tool we wrote in the C 
programing language, with default parameters (https://github.com/DonFreed/find_denovo). 
find_denovo identifies alleles which are present in children but absent from their parents. It 
then applies a number of filters including a minimum number of reads for all trio members 
(20), a minimum number of reads supporting the alternate allele in the child (3), a minimum 
phred-scaled confidence for the presence of the de novo allele in the child (20) and the 
absence of the de novo allele in the parents (20), and a maximum number of individuals 
genotyped for the allele in the cohort (2). De novo variant effects were then annotated using 
SnpEff [238]. Families 11060, 11431, 11628, 11714, 11905, 12173, 12230, 12401, 12456, 
12809, 12879, 13143, 13949, 14025, and 14355 were excluded as more than 10 de novo 




Mosaic variants were identified from de novo variants using the binomial test to 
examine the alternative hypothesis that the de novo allele is supported by significantly fewer 
sequence reads than expected from the read depth. We use p = 0.5 as the expected fraction of 
sequence reads supporting the de novo allele. p-values were adjusted using the Benjamini-
Hochberg procedure with a FDR of 0.05 and variants with q < 0.05 were called mosaic. In 
the final callset we add the requirement that mosaic variants must have an AARF of less than 
34%. In addition, mosaic variants that were identified uniquely in our callset and not in the 
callsets produced by Iossifov et al. or Krumm et al. were filtered.  
3.2.8 Phasing of variants in the Simons Simplex Collection 
Variants identified as de novo in the Simons Simplex Collection were phased to 
nearby inherited variants to validate mosaic status and to determine the parental haplotype of 
the variant allele using phase-mosaic, a tool we wrote in Java and Python 
(https://bitbucket.org/donald_freed/phase-mosaic, version f47bcd). For each identified de 
novo variant, sequence data 500bp upstream and downstream of the variant was downloaded 
to the local machine from AWS Simple Storage Service (S3) for each member of the 
pedigree. Variants were then recalled using the GATK version 3.5-0 compiled with the 
VariantReadIds annotation. Phasing was then performed on the resulting VCF files. 
3.2.9 Rates of mutation in the Simons Simplex Collection 
Regions of 40x coverage were defined for each individual in quad families using 
BEDtools genomecov –bga with the resulting BedGraph file converted to a BED file using a 
custom script [239]. BEDtools was then used to intersect the 40x BED file for each member 
of a trio and the target capture file to produce a joint 40x BED file for the trio. Variants in the 




custom scripts. The length of the genome present in the joint 40x region was recorded for 
each child in a quad family. Finally, the rate of de novo mutation for each individual and 
each class of mutation was calculated from the size of the joint 40x region and the number of 
mutations in joint regions identified in the child. These rates were then extrapolated to the 
entire capture region. 
Iossifov et al. previously reported a model of de novo variation in which siblings have 
a baseline rate of de novo mutation while probands have the same baseline rate and 
additional mutation due to their affected status [212]. We expand this model to distinguish 
between germline de novo and mosaic variation while incorporating errors in classification of 
mosaic status. In siblings the observed rate of mosaic or germline de novo variation was 
modeled as the sum of correctly and incorrectly classified baseline variation. In probands the 
models included correctly and incorrectly classified contributory variation in addition to the 
baseline variation. Classification error rates were for siblings modeled as either incorrectly 
classified baseline variation over correctly and incorrectly classified baseline variation. For 
probands, classification error rates were modeled as incorrectly classified baseline and 
contributory variation over correctly and incorrectly classified baseline and contributory 
variation.  
These models were solved to obtain the rate and fraction of contributory variation 
using the observed rates of mutation and classification errors as measured by phasing 
validation. Classification error rates were calculated separately for probands and siblings and 
for germline de novo and mosaic classification. Uncertainty in classification error rates was 




parameters. A 95% credible interval was obtained through 10,000 permutations with 
classification error rates obtained by random draws from their respective distributions. 
3.2.10 Simons Simplex Collection variant conservation 
Variants were annotated with PhyloP conservation score, taxonomic conservation as 
reported by NCBI’s HomoloGene database, and the probability of null mutations being 
deleterious (“pNull”) as reported by ExAC [240-242]. BigWig files containing genome-wide 
PhyloP scores were downloaded from UCSC 
(ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/phyloP100way/hg19.100way.phyloP100wa
y.bw; accessed Nov. 10
th
, 2015) and were used to annotate variant conservation. Gene-level 
conservation was annotated by querying the NCBI’s HomoloGene database using Biopython 
and Entrez to find the earliest taxonomic unit reported to sharing the gene containing the 
mutation [243]. These taxonomic units were then converted to numeric scores where 0 
corresponds to conserved in Homo while 31 corresponds to conserved to the root of the 
HomoloGene taxonomic tree. ExAC gene summary data were downloaded from 
(ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3/functional_gene_constraint/READ
ME_fordist_cleaned_nonpsych_z_data_pLI_2016_01_13.txt; accessed Feb. 11
th
 2016) and 
variants were annotated with the reported probability of their respective gene being intolerant 
of loss-of-function mutation. Using these data, mutations present in probands were compared 
to mutations present in siblings with the Wilcoxon rank sum test.  
3.2.11 Gene target overlap and recurrence 
Methods for analysis of gene target overlaps and recurrence were adopted, with 
modification, from Iossifov et al. [212]. RefSeq genes were downloaded from the UCSC 
Table Browser (https://genome.ucsc.edu/cgi-bin/hgTables; accessed Jul. 16
th




“chr” prefix was removed from the chromosome names and the raw table was sorted by 
chromosome and position. Coordinates of coding sequence starts and stops were extracted 
from the RefSeq table in BED format using custom scripts and overlapping coding sequences 
were merged using BEDtools [239]. This file was intersected with the BED file of the target 
capture region and the length of each gene in the target region was calculated. These data 
were then combined with data of gene membership in gene sets from Supplementary Table 7 
of Iossifov et al. and the high-quality callset to produce a table describing the number of 
observed mutations in each gene and each gene’s set membership [212]. 
Given their observed contribution to ASD diagnosis, only mosaic missense and 
germline de novo LGD mutations were analyzed and these mutations were analyzed in both 
probands and siblings. These analyses were performed using a null length model where the 
probability of a mutation occurring within a gene is proportional to its length targeted for 
exome capture relative to the total size of the capture target. For every mutation-type, 
individual combination, we calculate the following: (1) The expected number of recurrent 
mutations and a p-value for the observed number of recurrent mutations from 10,000 
simulations using sampling with replacement. (2) For each gene set from Iossifov et al. we 
calculate the expected number of genes harboring mutation present in the gene set, given the 
length of capture targets of genes within the set relative to the total length of all gene capture 
targets. Using a two-sided binomial test, we test for observed enrichment or depletion from 
the expectation based on the null length model. 
For testing the enrichment of mosaic missense and LGD mutations in genes 
implicated in ASD, we used the approach described above with the target gene set of 107 





Amplification and sequencing primers were designed for all loci using PyroMark
TM 
software and the NCBI’s Primer-BLAST [244]. Additionally, primers were checked for 
overlap with common SNPs using the UCSC Genome Browser [245]. Samples were 
amplified according to protocols in the Qiagen Pyromark PCR kit with a single biotinylated 
primer. Pyrosequencing was performed and data were analyzed by the Johns Hopkins 
Genetic Resources Core Facility. 
3.2.13 Amplicon-targeted sequencing 
Sequence libraries were generated from purified DNA according the Nextera XT 
DNA Library Preparation Guide. Sequence data were then generated on an Illumina MiSeq 
using a MiSeq Reagent Kit v2. Sequence reads were aligned to the human reference genome 
(UCSC hg19) using BWA and reads supporting the reference or alternate alleles were 
counted [234]. 
3.2.14 Sanger Sequencing 
Mosaic variants and germline de novo variants for validation were chosen at random 
from variants present in samples on hand. In total 97 variants were chosen for validation, 50 
germline de novo variants and 47 mosaic variants. Primers for polymerase chain reaction 
amplification were designed using Primer-BLAST [244]. Amplification was performed using 
DNA isolated from whole blood and Sanger sequencing was performed at the Johns Hopkins 
University School of Medicine Synthesis and Sequencing Facility. 
3.3 Results 




Obligatory somatic mutations typically occur in a localized fashion in tissues that 
share a common developmental origin. To examine the contribution of tissue-specific 
mutations in ASD, we generated whole-exome sequence data from paired postmortem frontal 
cortex (n = 16) and heart (n = 14) or kidney (n = 2) samples from individuals diagnosed with 
ASD (n = 12) and controls (n = 4). Sequence data were generated using the Illumina HiSeq 
platform with an average sequence depth of 95x across capture targets (Table 3.1; Table 
3.2). Variants were detected using the somatic variant callers Strelka and Mutect [132,133]. 
These programs detect mutations unique to single tissues from paired samples. Analyzing 
frontal cortex/heart or frontal cortex/kidney pairs resulted in the identification of 373 mosaic 
variants in the 32 samples. However, validation experiments indicated that all potential 
mutation loci were homozygous for the reference allele (i.e. all mutations chosen for 
validation were false positives; Figure 3.1; Tables 3.3 to 3.7). Our findings agree with 
previous results that tissue-specific mosaic mutation in brain rarely occurs at the level of 





Figure 3.1. Quality metrics of GIAB variants and MuTect calls. 
(A) Principal components of scaled variant features in the GIAB callset visualized by log-
transformed density (blue) overlaid with variants called by MuTect (red). Much of the 
density of GIAB variants was clustered around (0,0), with the MuTect variants having 
significantly more spread. 96.0% of GIAB variants cluster within a Euclidian distance of 
three from the origin, as did only 41.5% of variants called by MuTect. (B) Noise 
measurement in the GIAB and MuTect variants (log-scale). MuTect variants were called at 
sites with drastically more noise. While only 0.3% of GIAB variants had an allelic noise 










Table 3.7. Tissue-specific mosaic indels identified by Strelka.  
Attempted validation of variants by targeted sequencing (orange) is indicated. 
Brain 





1349B 20 18123040 TTG T 66;0 41;5 
4671B 4 15987514 A AGT 28;0 43;16 
4671B 4 15987515 A ATGCT 30;0 48;16 
4671B 6 160132143 CCACTCACATTGCTCTGAT C 95;0 46;4 
4907B 7 74191612 GGT G 84;0 51;6 
5144B 7 116955170 ATCCTT A 84;0 69;3 
5144B 11 66411363 AGCTGCTGCTGCAGCAGCAGCC A 156;0 169;4 
5391B 1 241846828 CTG C 66;0 42;6 
5391B 19 17918776 A AC 118;0 105;10 
5408B GL000220.1 119444 GCTCTCGCT G 167;1 164;5 
4722H 16 89299768 G GCAAAT 93;0 49;6 
4722H 17 79866732 G GC 83;0 36;3 
4722H GL000220.1 131171 T 
TTCTCTCTGT
C 150;0 114;8 
4671H 7 21659554 A ATTAAT 70;0 67;3 
4671H 8 10467680 TTCCTTC T 331;0 461;14 
4849H 1 172387390 ATTTTG A 120;0 96;4 
4849H 17 1585378 AACCACC A 81;0 62;3 
5144H 1 16376516 CAT C 15;0 0;5 
5278H 20 16362789 GGA G 59;0 32;8 
5391H 9 116184795 ATGTTT A 73;0 54;3 













4899B 6 160132562 CCACTCACATTGCTCTGAT C 189;0 224;18 
4899B 9 139910402 CAG C 97;0 45;4 
4899B 19 39220200 G GGC 26;0 19;7 
5176B 1 248616704 CTGCTGCG C 335;1 97;4 
5176B 9 138899193 GCA G 72;1 38;21 
5176B 9 138899204 GAC G 72;0 34;19 
5176B 9 138899222 TAC T 57;0 31;10 
5176B 16 30982808 ATCC A 63;0 20;4 
5176B GL000220.1 120208 GCTGCTGCCTCTGCCTCCACGGTT G 161;0 138;5 
797H 14 20146543 A AGTCCC 257;0 144;4 
797H 16 4796952 TGAG T 66;0 36;6 
797H 16 24574672 TCTGGC T 92;0 72;3 
4899H 1 248616704 CTGCTGCG C 419;0 152;13 
4899H 9 135962590 CTGT C 26;0 5;10 
4899H 9 135962599 C CG 30;0 6;9 
4899H 9 135962600 C CT 31;0 7;9 
4899H 19 53418429 A ACTTCT 73;0 82;6 
5115H 3 53145933 GAAAAC G 95;0 73;3 
5115H 9 35364644 ATG A 38;0 7;4 
       
Validation Legend: 
     
Targeted Sequencing 




3.3.2 Detection of mosaic mutations from single samples 
In next-generation sequencing data, reads supporting the alternate allele at variant 
sites are known to be under-represented due to biases against non-reference alleles [247]. 
Further, many variant callers explicitly assume a diploid model. Therefore, the extent to 
which existing germline variant callers accurately genotype mosaic mutations in unpaired 
samples is uncertain. To evaluate our ability to discover mosaic mutation occurring in single 
samples, we obtained the Illumina Platinum Genomes sequence including NA12878, an 
individual for whom a high-confidence callset is available (ERP001960) [248]. We then 
characterize the sensitivity of the GATK HaplotypeCaller for mosaic variants through in 
silico mixture experiments (Figure 3.2). For this experiment, we utilized 200x sequence data 
from the Illumina Platinum Genomes (ERP002490; See Materials and Methods). Sequence 
reads from NA12878 were mixed with sequence reads from her son NA12882 over regions 
known to harbor variants from the high-confidence GIAB callset. Mixtures were then 
subsampled to depths of 30x and 50x with random fractions of reads from N12878 and 
NA12882. Variants were then called from the mixture and the sensitivity of the variant caller 
was assessed for variants known to be present in NA12878 but not NA12882. Sensitivity was 
also assessed with different values of –ploidy argument which alters the expected AARFs of 
heterozygous variants. These results demonstrated that higher –ploidy settings improved 
sensitivity for low frequency mosaic variants at the cost of higher memory usage and longer 






Figure 3.2. Performance evaluation of submixbam. 
(A and B) Evaluation of subsampling functionality of submixbam. Target depths are 
consistent with measured depth across a range of target depths. (C and D) Evaluation of 
mixing functionality of submixbam. submixbam performed highly precise and accurate 





Figure 3.3. Sensitivity of the GATK HaplotypeCaller for mosaic variation. 
(A) Sensitivity of the HaplotypeCaller for simulated mosaic variants from real sequence data 
at a sequencing read depth of 50x using various ploidy arguments. Higher ploidies resulted in 
higher sensitivity. (B) Comparison of ploidy 2 and ploidy 5 at 30x and 50x depth. Higher 





3.3.3 Mosaic mutations in the Simons Simplex Collection 
Given that mosaic variants may be identified with germline variant callers, we sought 
to determine the mosaic status of variants in the Simons Simplex Collection (SSC), a large 
collection of simplex autism pedigrees [249]. Extensive phenotypic data and whole-exome 
sequence data have been generated for all members of the collection and two non-
overlapping callsets have been generated from the SSC exomes [212,228]. To increase 
sensitivity for detection of mosaic variants we performed a complete re-calling of all samples 
in the SSC with a –ploidy 5 setting (Figure 3.4). Variant filtration was performed using the 
GATK’s variant quality score recalibration (VQSR) pipeline and de novo variants were 
identified using find_denovo with default parameters. This resulted in the identification of 
6,408 de novo variants, of which 3,355 and 228 were present in the Iossifov or Krumm 
callsets, respectively and 2,825 were unique to our callset. Average coverage of high quality 
sequence reads at positions with identified de novo variants was 94.6, indicating that mosaic 
variants are likely to be accurately detected, when they occur. Of variants identified by 
Iossifov et al. or Krumm et al. but excluded from our callset the majority were filtered by 
VQSR (Table 3.8). We excluded fifteen families who had a child with more than 10 de novo 
mutations since these likely occur due to technical artifacts. After exclusion of these families, 
our callset contained 4,909 de novo variants. Variant effects were annotated using SnpEff 
and mosaic variants were identified from a binomial test with false-discovery protection 
using the Benjamini-Hochberg procedure [238]. This resulted in the identification of 1,036 
mosaic variants at an FDR of 5%. Hereafter, we will refer to the variants identified as de 






Figure 3.4.  Overview of the pipeline for calling variants in the Simons Simplex 
Collection. 
For each step the total size of compressed data is given (e.g. 20 TB), number of individuals 
or files, analysis tool (e.g. Genome Analysis ToolKit [GATK] argument), average runtime 
job, and Amazon Web Services (AWS) EC2 instance type used in the analysis (e.g. 
c3.xlarge). Abbreviations: gVCF, genomic Variant Call Format file; glusterFS, a scalable 
network file system; NAS, network attached storage. Analyses were performed using AWS 









Table 3.8. Summary of the relationship between the Krumm/Iossifov callsets and the current callset. 
Filters are applied from left to right. The VQSR column shows the number of variants filtered by the GATK’s Variant Quality Score 
Recalibration pipeline. The columns called in father and called in mother indicate that the variant was genotyped as present in the 
father or mother, respectively. The column child alt DP indicates that fewer than three sequence reads passing quality filters were 
observed to support the alternate allele in the child. The columns child DP, father DP, and mother DP indicate a depth of less than 20 
sequence reads were observed in the child, father, or mother, respectively. The columns child PL, father PL, and mother PL indicate a 
phred-scaled likelihood for the presence of the genotype (in the child) or the absence of the genotype (in the parents) of less than 20. 
The column multiple individuals shows the number of variants filtered due to their presence in more than two individuals. 
 
 




























individuals remaining filtered 
Krumm 1544 28 169 732 3 2 4 100 100 52 0 57 48 21 228 1316 
Iossifov 5690 335 141 995 21 63 4 89 35 39 0 98 100 415 3355 2335 




To ensure that the variants in our callset were present in the samples, we performed 
Sanger sequencing of 97 (47 mosaic and 50 germline de novo) variants (Table 3.9, pre-
filter). For all of our validation methods, we present both “detection precision” and 
“classification precision”, where applicable. We define “detection precision” as our precision 
for the presence of the variant in the sample, while we define “classification precision” as our 
precision for the presence of the variant in the sample and correct classification of the variant 
as either mosaic or germline de novo. Of the 97 reactions, sequencing was informative for 76. 
The variant of interest was identified in 100% of samples when the variant was annotated as 
germline de novo. However, in samples harboring a mosaic variant, precision for the 
presence of the variant was modest (54%). Mosaic variants that failed validation were often 
called with few reads supporting the alternate allele and were frequently called uniquely in 
our callset. To improve downstream analyses, we made the conservative choice of requiring 
that identified mosaic variants be present jointly in our callset and in the Iossifov or Krumm 
callsets. This filter greatly improves the precision of our callset (100% for variant presence; 
Table 3.9, post-filter) with little change in sensitivity. However, the precision of the 






Table 3.9. Sanger sequencing validation of variants in the Simons Simplex Collection. 
Pre-filter mosaic variants were identified as described in the methods section. Post-filter 
mosaic variants have the additional requirement that they must be identified jointly in the 
current callset and one of the callsets produced by Iossifov et al. or Krumm et al. Assay 
success refers to technical success of the sequencing assay. 
 










Pre-filter Mosaic 47 37 20 0.54 14 0.37 
 Germline 
de novo 
50 39 39 1.00 3 0.92 
Post-filter Mosaic 26 19 19 1.00 13 0.68 
 Germline 
de novo 






While Sanger sequencing provides an accurate assessment of the presence of de novo 
variants, examination of the chromatograms can provide only approximate estimation of 
mosaic status. To more accurately assess the mosaic status of the identified variants, we 
performed sequence read phasing of all identified de novo variants. Phasing of the potential 
mosaic variants relative to nearby inherited heterozygous variants using sequence reads may 
rigorously confirm the presence of mosaicism. This occurs when three parental haplotypes 
are inferred: a single haplotype from one parent (e.g. having the minor allele of the 
neighboring SNP), and two haplotypes from the other parent (e.g. having the major allele of 
the neighboring SNP) which resolve into a haplotype with the mosaic allele and a distinct 
haplotype lacking the mosaic allele (Figure 3.5). We wrote a program called phase-mosaic to 
perform phasing validation (see Materials and Methods). Of the variants passing filters, 
phasing was informative for 51 mosaic variants of which 29 were validated as mosaic (57%; 
Table 3.10, Pre-filter). Mosaic variants identified by next-generation sequencing that failed 
phasing confirmation tended to be variants called at high depth with a high AARF. We 
suspect that these variants appear to be mosaic due to preferential capture of the reference 
allele during exome enrichment. To correct for this effect, we modified our criteria for the 
identification of mosaic variants to require that mosaic variants have AARF less than 34%. 
With these adjusted parameters, the precision of our classification of mosaic status improved 






Figure 3.5. Confirmation of mosaic status by sequence read phasing.  
Phasing of a de novo variant confirms mosaic status of a variant in OR4M2 in individual 
12977.s1. The heterozygous variant on the left is inherited (green pattern; unknown parental 
origin). The deletion on the right was identified as occurring de novo. The presence of 
multiple reads (box) containing the inherited allele but not the de novo variant demonstrates 






Table 3.10. Read-backed phasing validation of the mosaic status of identified variants. 
Pre-filter mosaic variants were identified using the binomial test resulting in moderate 
sensitivity for mosaic status. Post-filter mosaic variants had the added requirement of an 
AARF of less than 34%, improving classification precision. 
 






Pre-filter Mosaic 342 51 29 22 0.57 
 Germline de novo 3742 443 27 416 0.94 
Post-filter Mosaic 221 30 26 4 0.87 






Validation of mosaic variants was also performed using pyrosequencing (Table 3.11). 
Likely-gene disrupting (LGD) and missense variants in probands across a range of allele 
frequencies were chosen for pyrosequencing validation (see Materials and Methods). 
Consistent with the post-filter results of Sanger sequencing and physical phasing, 
pyrosequencing validation demonstrated high precision for variant detection and variant 
classification (Table 3.12). Of all variants validated by an orthogonal sequencing technology, 
16 were validated with multiple validation methods. The results were consistent, except for 










Table 3.11. Pyrosequencing validation of de novo variants in the Simons Simplex Collection. 
Experiment 








alt p-mosaic Notes 
8/11/2015 13 51948834 14687 pM INTS6 G A 61 39 0.000261 
 8/11/2015 11 93463107 14069 pM CEP295 C CA 46 54 0.010037 
 8/11/2015 3 20161089 11592 pM KAT2B G A 49 51 9.76E-06 
 8/11/2015 13 92345513 11042 pM GPC5 T C 69 31 2.45E-07 
 8/11/2015 1 3385486 13350 pM ARHGEF16 C T 79 21 0.001444 
 8/7/2015 19 55439074 13199 pF NLRP7 C G 79 21 1.79E-05 
 8/7/2015 15 66198459 12056 pM MEGF11 G A 69 31 8.69E-12 
 8/7/2015 13 51948834 14687 pM INTS6 G A 65 35 0.000261 Warning 
8/7/2015 13 92345513 11042 pM GPC5 T C 64 36 2.45E-07 
 8/7/2015 12 116424952 14416 pM MED13L C T 46 54 0.586798 
 8/7/2015 11 64939990 14592 pM SPDYC C T 46 54 0.623983 
 8/7/2015 9 95277357 13364 pM ECM2 G A 49 51 0.872848 Warning 
8/7/2015 2 234676519 14644 pM UGT1A10 C T 53 47 0.918288 
 8/7/2015 2 127944869 14307 pM CYP27C1 AC A 53 47 0.924205 
 8/7/2015 7 104748100 12952 pM KMT2E TC T 35 65 0.99024 
 8/7/2015 15 41192955 13575 pM VPS18 C T 75 25 0.006765 
 8/7/2015 2 6990025 13254 pM CMPK2 G A 50 50 0.032623 
 8/7/2015 13 21205235 14226 pM IFT88 T G 53 47 0.040345 
 8/7/2015 8 124787443 12221 pM FAM91A1 C T 50 50 0.015241 
 8/3/2015 7 100850973 13846 pM PLOD3 C T 70 30 9.85E-07 
 7/28/2015 7 100850973 13846 pM PLOD3 C T 75 25 9.85E-07 
 7/17/2015 10 876865 14093 pM LARP4B TCA T 90 10 3.62E-14 
 7/17/2015 4 80954694 13848 pM ANTXR2 C T 65 35 5.24E-09 
 7/2/2015 10 876865 14093 pM LARP4B TCA T 81 19 3.62E-14 

















alt p-mosaic Notes 
7/2/2015 2 234676519 14644 pM UGT1A10 C T 43 57 0.918288 
















Mosaic 11 11 1.00 9 0.82 
Germline 







After the application of filters, we identified a total of 4,095 de novo variants in our 
high-confidence callset, 221 of which were classified as mosaic. Based on our validation 
experiments, we estimate that our precision for the presence of the called variants is near 
100% with the precision of the classification of mosaic variants measured at 87% or 82% by 
phasing or pyrosequencing, respectively. Of the variants in our final callset, 3,351 appear 
jointly in the current callset and the callset produced by Iossifov et al. while 228 appear 
jointly in the current callset and the callset produced by Krumm et al. (Figure 3.6). In the 













3.3.4 Properties of mosaic variants 
To better understand the properties of variants in our callset, we examined the 
mutational spectra of the identified mosaic variants relative to germline de novo variants 
(Table 3.13). We find that mosaic variants have significantly more deletions than germline 
de novo variants (Fisher’s exact test, p = 5.2e-4). However, the rate of occurrence of other 
types of mosaic mutations is approximately equal to the rate of occurrence of the 
corresponding de novo mutation. The relative enrichment of mosaic mutations for deletions 
may indicate an increased rate of false-positive mutation as the identification of indels from 
next-generation sequence data is known to be difficult. However, our precision when 
validating mosaic mutation was quite high (see above). We attempted validation of four 
deletions in the high-confidence callset using Sanger sequencing. All four deletions were 
found in the sample and three of four were confirmed as mosaic. Besides false-positives, the 
enrichment of mosaic mutations may indicate a non-reference allele bias, where germline de 
novo deletions are occurring in the samples but are incorrectly classified as mosaic due to 
mapping errors. Phasing assessed the mosaic status of eight mosaic deletions, six of which 
were confirmed as mosaic resulting in a classification precision of 75%, slightly less than the 
overall classification precision of 87% from sequence read phasing. Therefore, inaccurate 
classification of the mosaic status of de novo deletions may contribute to the observed 
enrichment. An additional hypothesis is that the mechanism underlying mosaic mutation 
wholly or partly differs from that of germline de novo mutation and the relative enrichment 




Table 3.13. The mutation spectra of mosaic variants relative to germline de novo 
variants. 
Odds ratios of less than 1 indicate mosaic variants are relatively depleted for those events 
while odds ratios of greater than 1 indicate relative enrichment. p values were calculated 
using a Fisher’s exact test. 
Mutation Type Odds Ratio p-value 
transition 0.88 0.265 
transversion 1.10 0.503 
insertion 0.83 1.000 
deletion 2.49 0.001 






3.3.5 Rates of mosaic mutation 
Previous studies have indicated that de novo mutations occur at higher rates in 
probands relative to controls leading to the implication of de novo variants as contributing to 
disease diagnoses [212,230]. We utilized our high-confidence mosaic variant callset to 
compare the rates of mosaic and germline de novo mutation in probands relative to 
unaffected siblings. Following the protocol of Iossifov et al. we defined regions of joint 40x 
coverage in children of quad families and extrapolated rates of mutation within these joint 
40x regions to the entire capture region (Figure 3.7; Table 3.14). Consistent with previous 
results, we find that germline de novo LGD mutations are significantly enriched in probands 
relative to controls (p=0.001). In addition we find that all classes of mosaic mutations are 
significantly enriched in probands (p=0.003). Interestingly, we observe contribution to 
disease from all classes of mosaic variation, whereas the contribution of germline de novo 






Fig 3.7. Rates of mutation in the Simons Simplex Collection. 
Average number of mutations per exome, as calculated using joint 40x regions. Error bars 
represent the 95% confidence interval for the mean. (A) Mutations categorized as mosaic 
with AARF < 0.34 and q < 0.05. (B) Germline de novo mutations as determined by q > 0.05 










Table 3.14. Rates of de novo mutation in individuals in the Simons Simplex Collection. 
















mean 95% CI 
Sibling mean 
95% CI p-value 
non_mosaic_lgd 0.134 0.486 0.084 0.374 0.373 0.050 0.02272 0.01748 0.001 
non_mosaic_missense 0.578 1.022 0.543 0.949 0.060 0.034 0.04775 0.04437 0.301 
non_mosaic_synonymous 0.203 0.595 0.214 0.616 -0.058 -0.012 0.02780 0.02877 0.563 
non_mosaic_noncoding 0.011 0.133 0.016 0.163 -0.396 -0.004 0.00619 0.00760 0.379 
non_mosaic_other 0.057 0.333 0.056 0.329 0.021 0.001 0.01555 0.01539 0.914 
non_mosaic_all 0.982 1.335 0.913 1.254 0.071 0.069 0.06241 0.05863 0.113 
mosaic_lgd 0.017 0.211 0.010 0.143 0.395 0.007 0.00985 0.00666 0.263 
mosaic_missense 0.051 0.303 0.033 0.252 0.344 0.018 0.01418 0.01178 0.063 
mosaic_synonymous 0.015 0.168 0.007 0.105 0.534 0.008 0.00786 0.00492 0.095 
mosaic_noncoding 0.000 0.000 0.000 0.000 - 0.000 0.00000 0.00000 - 
mosaic_other 0.007 0.120 0.001 0.044 0.847 0.006 0.00562 0.00206 0.046 
mosiac_all 0.090 0.442 0.052 0.309 0.424 0.038 0.02067 0.01444 0.003 
          n-probands 1758 
        n-sibs 1758 





To account for errors in the classification of variants as either mosaic or germline de 
novo, we extended our model of contributory variation to include incorrectly classified 
variants. In this model, mosaic variants incorrectly classified as germline de novo account for 
a substantial portion of the genetic contribution of variants classified as germline de novo 
(Figure 3.8). In total, mosaic variation contributes to 5.1% of ASD cases (95% credible 
interval [CI], 1.3% to 8.9%) while all classes of germline de novo variation contribute to 
5.6% of ASD cases (95% CI, 1.8% to 9.4%). The percent of contributory variants to total 
variants are measured as 6.0% (95% CI, 2.0% to 10%) and 33% (95% CI, 9.6% to 54%) for 






Figure 3.8. The contribution of de novo mutations to ASD. 
The contribution of classified mosaic and germline mutations are shown. For each 
classification, the contribution is divided into correctly classified and incorrectly classified 
variation. The contribution of incorrectly classified mosaic variants (called germline; left bar, 
upper region) is substantial, but the contribution of incorrectly classified germline variation 






3.3.6 Functional consequences of de novo mutation in the SSC 
While differences in the rates of mutation in affected individuals may implicate 
mutations in disease, it may also be the case that mutations in probands occur in more 
functionally conserved genomic regions. Using all of the mutations in our high-confidence 
callset, we test the hypothesis that mutations in probands occur at more conserved genomic 
regions. For this analysis, we use three measures of conservation: base-level conservation as 
measured by PhyloP, and gene-level conservation as measured by HomoloGene or ExAC 
(Table 3.15) [240-242]. The gene-level conservation measures from ExAC and Homologene 
are complimentary as HomoloGene provides a measure of evolutionary conservation while 
ExAC provides a measure of conservation in extant human populations. We find that 
germline de novo LGD mutations occur at more highly conserved positions in probands 
relative to controls as measured by PhyloP score (p = 0.048, effect = 0.54). For mosaic 
missense mutations, we observe a stronger effect (0.91), although the test does not reach 
statistical significance due to the small sample size (p = 0.179). We find that germline de 
novo missense variants occur significantly more often in genes thought to be intolerant of 
loss-of-function mutation as annotated by ExAC (p = 0.013). While our analysis does not 
show that germline de novo missense mutations occur at significantly higher rates in 
probands relative to siblings (p = 0.30), germline de novo missense variants likely target 






Table 3.15. Conservation at sites of de novo variation in probands and siblings. 
Each variant was annotated with measures of conservation as described in the Methods 
section. Measures of conservation were compared between probands and unaffected siblings 
and p values were calculated using a Wilcoxon rank sum test. Estimates of effect size were 
calculated as the estimated difference in ranks. 
 
PhyloP Score HomoloGene ExAC 
 
Effect_Size p-value Effect_Size p-value Effect_Size p-value 
mosaic_missense 0.91 0.179 6.90E-05 0.222 2.29E-05 0.534 
non-mosaic_missense 0.16 0.250 -6.33E-05 0.735 -1.02E-06 0.013 
mosaic_LGD 0.46 0.679 4.70E-05 0.808 3.27E-05 0.894 






The initial publication of the SSC exome sequencing data demonstrated enrichment 
of mutations in specific classes of gene targets [212]. To find insight into the mutational 
mechanisms and functional consequences of mosaic mutation, we replicated this analysis 
(with modification) using our high-confidence callset. This analysis confirmed the significant 
enrichment of germline de novo LGD mutations from probands in FMRP targets, chromatin 
modifiers, and genes with known LGD mutations in intellectual disability or schizophrenia 
(Table 3.16). In addition, we observed enrichment of mosaic missense and LGD mutations in 
probands and siblings in genes involved in embryonic development (18 observed versus 12.6 
expected for probands; 9 observed versus 6.7 expected for siblings), however this enrichment 
did not reach statistical significance (p = 0.12 for probands; p = 0.30 for siblings). We also 
tested for overlap between genes targeted by mosaic missense and LGD mutations and a set 
of 107 genes that had been strongly implicated in ASD using the null-length model (see 
Methods) [210]. We found three of the 98 genes with mosaic missense or LGD mutations in 
probands have been previously implicated in ASD (KMT2C, NCKAP1, and MYH10). The 
presence of the NCKAP1 was confirmed by Sanger sequencing, but did not confirm its 
mosaic status. However, the number of mosaic mutations in ASD genes does not reach 
statistical significance for enrichment in the set of 107 ASD genes (3 observed; 1.15 
expected; p = 0.109). Zero of 52 genes targeted by mosaic missense or mosaic LGD 











Table 3.16. Gene target overlap. 
Columns describe gene target enrichment analysis. 
class 
Set FMRP 









Set De Novo LGDs 
In Schizoprenia 
Set De Novo 






























1.00000) 0 (0.55, 1.00000) 
0 (0.17, 
1.00000) 













1.00000) 6 (2.01, 0.01647) 
5 (0.64, 
0.00051) 





















There are three major conclusions from this study. First, we show that mosaic 
mutations occur frequently in individuals diagnosed with ASD and their unaffected siblings. 
We identify a total of 4,095 de novo mutations, of which 221 (5.4%) are classified as mosaic. 
This is similar to previously reported estimates for the fraction of mosaic variants in 
individuals with intellectual disability [233]. In light of previous work demonstrating the 
presence of mosaic mutation in diverse body tissues we believe that the mosaic mutations we 
identified are not unique to blood but are dispersed throughout the body [202]. Although the 
early steps of our pipeline were performed explicitly to increase our sensitivity for mosaic 
mutation, many of our filtering steps were conservative and we likely underestimate the true 
fraction of mosaic mutations in the Simons Simplex Collection. Our filtering approach 
combined with recent improvements in variant detection algorithms likely accounts for most 
of the differences between our variant callset and the callsets published by Iossifov et al. and 
Krumm et al.  
Second, we find that mosaic mutations are significantly enriched in probands relative 
to their siblings. Using our model of contributory variation we estimate that 33% of mosaic 
mutations contribute to 5.1% of ASD diagnoses. As mosaic mutations arise post-zygotically 
in only a fraction of the cells of an individual, we expect that these results have implications 
for the interpretation of twin studies, especially observed cases of phenotypic discordance 
between monozygotic twins.  
Third, we find that tissue-specific mosaic mutations do not occur in the paired 
samples at our limit of detection. Given the lack of publications on validated tissue-specific 




a centenarian [246], we do not believe that this finding is unexpected. While a recent study 
reported tissue-specific mosaic mutation [250], the results presented here include validation 
of detected mutations showing that, in our study, these were false positive findings. It is 
possible that tissue-specific mutations do contribute to ASD in at least some cases. However, 
discovery of such variation and its implication in disease may require larger numbers of 
samples or more sensitive approaches (such as single-cell sequencing). 
Together, these results indicate that mosaic mutations are an identifiable subset of de 
novo mutation. As heritable factors that may arise in a single twin of a monozygotic pair 
[231,232], contributory mosaic mutation implies some expected level of discordance between 
monozygotic twins due to heritable factors arising post-zygotically. Furthermore, high-
confidence identification of contributory mosaic mutation in affected probands implies a 
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